Skip to main content
Wellcome Open Research logoLink to Wellcome Open Research
. 2024 Oct 18;9:64. Originally published 2024 Feb 19. [Version 2] doi: 10.12688/wellcomeopenres.20557.2

Investigating light sensitivity in bipolar disorder (HELIOS-BD)

Amber Roguski 1,2,a, Nicole Needham 1,2, Tom MacGillivray 2,3, Jasna Martinovic 4, Baljean Dhillon 2, Renata L Riha 2,5, Lyle Armstrong 6, Iain H Campbell 1,2, Amy Ferguson 1,2, Gerrit Hilgen 7, Majlinda Lako 6, Philipp Ritter 8, Nayantara Santhi 7, Malcolm von Schantz 7, Manuel Spitschan 9,10,11, Daniel J Smith 1,2
PMCID: PMC11074697  PMID: 38716042

Version Changes

Revised. Amendments from Version 1

This update reflects recent substantial amendments to the HELIOS-BD study, including changes to the inclusion & exclusion criteria and recruitment methods for participants. We also provide clarifications in response to reviewer feedback, and provide further information on aspects of the methodology such as the Part B pupillometry methods.

Abstract

Many people with bipolar disorder have disrupted circadian rhythms. This means that the timing of sleep and wake activities becomes out-of-sync with the standard 24-hour cycle. Circadian rhythms are strongly influenced by light levels and previous research suggests that people with bipolar disorder might have a heightened sensitivity to light, causing more circadian rhythm disruption, increasing the potential for triggering a mood switch into mania or depression.

Lithium has been in clinical use for over 70 years and is acknowledged to be the most effective long-term treatment for bipolar disorder. Lithium has many reported actions in the body but the precise mechanism of action in bipolar disorder remains an active area of research. Central to this project is recent evidence that lithium may work by stabilising circadian rhythms of mood, cognition and rest/activity. Our primary hypothesis is that people with bipolar disorder have some pathophysiological change at the level of the retina which makes them hypersensitive to the visual and non-visual effects of light, and therefore more susceptible to circadian rhythm dysfunction. We additionally hypothesise that the mood-stabilising medication lithium is effective in bipolar disorder because it reduces this hypersensitivity, making individuals less vulnerable to light-induced circadian disruption.

We will recruit 180 participants into the HELIOS-BD study. Over an 18-month period, we will assess visual and non-visual responses to light, as well as retinal microstructure, in people with bipolar disorder compared to healthy controls. Further, we will assess whether individuals with bipolar disorder who are being treated with lithium have less pronounced light responses and attenuated retinal changes compared to individuals with bipolar disorder not being treated with lithium. This study represents a comprehensive investigation of visual and non-visual light responses in a large bipolar disorder population, with great translational potential for patient stratification and treatment innovation.

Keywords: Bipolar disorder, lithium, melatonin, light sensitivity, circadian rhythm, vision, sleep, retina

2 Introduction

This protocol is one part from a broader programme of work funded by the Wellcome Trust entitled “Lithium’s mechanism in bipolar disorder: investigating the light hypersensitivity hypothesis”. This protocol relates to the three University of Edinburgh workstreams (Parts A, B and C) of HELIOS-BD as follows:

  • Part A: Non-visual responses to light in bipolar disorder

  • Part B: Retinal sensitivity in bipolar disorder and lithium therapy

  • Part C: Retinal imaging in bipolar disorder and lithium therapy

There are two other components of the broader research programme investigating a) responses of bipolar disorder retinal organoids to light and lithium (basic wet-laboratory research) and b) the effect of lithium on non-visual response to light in people with no history of mental illness (clinical trial). These components will be described in separate protocol papers.

2.1 Circadian rhythms are disrupted in bipolar disorder

Bipolar disorder is a severe mood disorder affecting 1–2% of the global population ( Merikangas et al., 2011). It is characterised by recurrent episodes of mania/hypomania and depression and is associated with a wide range of adverse health outcomes. Many of the clinical features of bipolar disorder – including extreme changes in mood, thinking, energy levels and rest/activity rhythms – can be conceptualised as fundamental disruptions of circadian rhythmicity ( McCarthy et al., 2022). This project investigates one hypothesised cause of this circadian dysregulation (light sensitivity) and a potential protective mechanism of action for lithium.

2.2 Circadian rhythms are entrained to light

Circadian rhythms are endogenous near-24-hour rhythms which are continuously synchronised with the external light-dark cycle. The mechanism of this photic entrainment begins with photon absorption by intrinsically photosensitive retinal ganglion cells (ipRGCs) in the retina. This signals the presence of light to the hypothalamic suprachiasmatic nucleus (SCN), the core regulator of circadian rhythms. There are two main effects of photic signalling from the retina to the SCN. Firstly, light exposure acutely (and reversibly) suppresses the primary circadian-regulatory hormone, melatonin. Melatonin receptors are found throughout the central and peripheral nervous systems; thus, circulating melatonin levels signal external timings to the body. Secondly, light exposure at specific time windows has the ability to entrain the SCN clock by adjusting its phase. Given that the average free-running human circadian period is slightly above 24 hours, light in the morning is critical for maintaining circadian synchrony, whereas artificial light in the evening has the potential to significantly disrupt (or delay) it. A hypo- or hyper-sensitive response to light within the photoreceptive pathway can therefore result in a shifted circadian phase and dysregulation of biological rhythms.

There are a range of sensitivities to light within the general population, reflecting the varying influences of age, sex, pupillomotor function, and environmental light exposure upon photic response ( Chellappa, 2020; Swope et al., 2023). However, light sensitivity has been shown to be enriched in particular populations, causing conditions such as delayed phase sleep wake disorder (DPSWD) ( Watson et al., 2018) which are characterized by considerable circadian dysregulation. Light sensitivity has also been identified as a feature of several mood disorders ( Swope et al., 2023) and thus represents an opportunity for improving understanding, treatment, and potentially prevention of these conditions.

2.3 Evidence for a light hypersensitivity in bipolar disorder

Since the 1980s, it has been hypothesized that photosensitivity to the non-visual effects of light could be the cause of the seasonal variation and circadian dysregulation seen in bipolar disorder populations. Disruption caused by hypersensitivity to light cues in bipolar disorder can lead to mood instability, disrupted sleep and ultimately episodes of hypomania, mania and/or depression (which themselves are characterised by circadian phase shifts ( Moon et al., 2016)). Seasonal patterns in bipolar mood episodes provide clinical support for this theory, with hospital admission data showing trends for more mania-related admissions in spring/summer and more depression-related admissions in autumn/winter ( Geoffroy et al., 2014). There is also an observed effect of seasonal changes in daily sunlight exposure on clinical outcomes such as suicide attempts ( Bauer et al., 2021).

As both circadian and circannual rhythms are strongly influenced by light levels, a sensitivity to light within the photoreceptive pathway could be the cause of disruption to biological rhythms in bipolar disorder. Specifically, large changes in light levels - for example, rapid changes in photoperiod length at the spring and autumn equinoxes, or due to trans-meridian travel - may have a detrimental impact on circadian rhythms and bipolar disorder symptoms.

Experimentally, it has been shown that individuals with bipolar disorder exhibit greater light-induced phase delays ( Ritter et al., 2021). Interventional studies in acute patient populations have also shown that blue-light blocking glasses may be effective in treating manic episodes ( Henriksen et al., 2016; Hester et al., 2021).

Melatonin suppression studies are the most direct way to test the causal effects of light on melatonin synthesis (and by proxy, circadian response to light). Several early studies showed that people with bipolar disorder have greater suppression of melatonin by light ( Hallam et al., 2009; Lewy et al., 1981; Lewy et al., 1985; Nathan et al., 1999), supporting a light hypersensitivity hypothesis. However, much of this research was conducted in small samples, and was conducted prior to the discovery of melanopsin in the late 1990s (thus missing a key piece of information regarding photoreceptive pathways). Several studies did not support a bipolar disorder light hypersensitivity ( Lam et al., 1990; Whalley et al., 1991), and although initial investigations suggested that light hypersensitivity might be a subpopulation feature of Type 1, but not Type 2, bipolar disorder ( Nurnberger et al., 2000), more recent research into this hypothesis have called this into question ( Ritter et al., 2020). To date, it has been difficult to establish clearly that light hypersensitivity is a feature of bipolar disorder because of poorly-controlled covariates within the small sample sizes reported in the literature. These limitations range from incomplete phenotyping of bipolar disorder participants, to a lack of measurement of pupil diameter and discrepancies in light delivery timing. Therefore, despite the intuitive potential of the light hypersensitivity hypothesis, current evidence is inconclusive.

Further, research investigating visual and non-visual responses to light have traditionally been siloed and there exists no complete theory of pathophysiological changes to the visual system in bipolar disorder which incorporates non-visual, circadian rhythm impacts. This is despite the knowledge that melanopsin-containing ipRGCs mediate visual-forming responses of retinal cone and rod cells ( Uprety et al., 2022). Research has shown that people with bipolar disorder (or bipolar disorder traits) exhibit altered, state-dependent pupillary responses to light ( Bullock et al., 2019; Madsen et al., 2021) and reduced colour discrimination ( Fernandes et al., 2017; Fernandes et al., 2022; Garcia-Martin et al., 2019) and visual processing ( Fernandes et al., 2019), indicative of alterations in retinal sensitivity. Further to these functional changes, retinal imaging studies have found structural changes to the vasculature and retinal layers in individuals with bipolar disorder ( Appaji et al., 2019; Garcia-Martin et al., 2019; Prasannakumar et al., 2023). It is not known whether, and how, these structural and visual function changes relate to non-visual responses in bipolar disorder.

2.4 A potential mechanism of action for lithium

Lithium has been in clinical use for over 70 years and is acknowledged to be the most effective long-term treatment for bipolar disorder. In the UK, the National Institute for Health and Clinical Excellence recommends lithium as a first-line treatment for bipolar disorder. However, lithium has variable efficacy within the bipolar disorder population, with roughly one third of individuals having a ‘full’ response. Lithium has many reported actions – including modulation of monoamine neurotransmission ( Ferrier et al., 2006), inhibition of glycogen synthase kinase-3 ( Klein & Melton, 1996), reducing the hyperexcitability of neurons and neuroprotection ( Mertens et al., 2015) – but the precise mechanism of action in bipolar disorder remains an active area of research. Given the considerable etiological and clinical heterogeneity of bipolar disorder, it is possible that lithium has different modes of action within different patient subgroups.

Central to this protocol is convergent evidence suggesting that lithium may work (at least in a proportion of patients) by stabilising aberrant circadian rhythms of mood, cognition and rest/activity. Animal studies demonstrate that lithium reduces light-induced phase delays ( Duncan et al., 1998) and that it modulates the pupillary response to light ( Seggie et al., 1989). In humans, 5 days of lithium ingestion was shown to significantly decrease melatonin suppression in healthy volunteers, with no significant effect on nocturnal melatonin secretion overall ( Hallam et al. 2005). Additionally, human MRI research showing that lithium accumulates in the eye ( Smith et al., 2018). Taken together, it is plausible that lithium’s circadian-regulating effects occur via an action at the level of the retina to reduce light sensitivity and non-visual response to light. If lithium were to normalise aberrant retinal signalling in some way, this may also reduce bipolar-specific visual responses to light. Further, sustained lithium use might be neuroprotective, preventing or attenuating progressive structural retinal changes.

2.5 HELIOS-BD study aims

The three-part HELIOS-BD protocol described here primarily seeks to investigate the light hypersensitivity hypothesis of bipolar disorder, with a mechanistic focus on the first component of the photoreceptive pathway: the retina. We hypothesise that retinal pathology causes light hypersensitivity in a proportion of people with bipolar disorder, which in turn increases susceptibility to circadian disruption and increases the risk of a mood episode. We will test whether structural and functional changes to the retina are progressive or stable with longitudinal data collection over 18 months. We will also test whether these bipolar-specific retinal changes cause changes to visual responses to light, using a range of psychophysical and electrophysiological methods. This project will therefore consolidate theories of visual and non-visual disturbances in bipolar disorder and will build an integrated picture of the bipolar disorder visual system.

These investigations will be expanded by incorporating lithium as a covariate and by assessing people with bipolar disorder either taking, or not taking, lithium. We hypothesise that lithium may be effective in bipolar disorder by acting at the level of the retina to reduce hypersensitivity to evening light. Specifically, we will assess visual and non-visual responses to light in people with bipolar disorder compared to healthy controls and, further, we will assess whether individuals with bipolar disorder who are being treated with lithium have responses to light that are attenuated compared to individuals with bipolar disorder not treated with lithium.

3 Protocol

3.1 Study objectives

The primary research question is ‘Do people with bipolar disorder have a hypersensitivity to visual and non-visual effects of light, and does lithium attenuate this hypersensitivity?’. This protocol is organized into 3 parts (Part A, B and C) to answer this question. The main objectives of each of these parts are as follows:

3.1.1 Part A objectives

  • 1.

    To assess whether people with bipolar disorder (relative to controls with no history of psychiatric disorder) exhibit greater non-visual responses to light stimuli assessed by the light-induced suppression of melatonin secretion.

  • 2.

    To assess whether these melatonin responses are less pronounced in those individuals with bipolar disorder who are being treated with lithium therapy (compared to individuals with bipolar disorder not taking lithium).

3.1.2 Part B objectives

  • 1.

    To characterize the visual, cortical and pupillary responses of people with bipolar disorder (relative to controls with no history of disorder) using a combined electrophysiological and psychophysical study protocol.

  • 2.

    To assess whether aberrant visual and non-visual responses are less pronounced in those individuals with bipolar disorder who are being treated with lithium therapy (compared to individuals with bipolar disorder not taking lithium).

3.1.3 Part C objectives

  • 1.

    To assess whether people with bipolar disorder (relative to controls with no history of psychiatric disorder) exhibit microstructural changes in the retina.

  • 2.

    To assess whether these changes are less pronounced in those individuals with bipolar disorder who are being treated with lithium therapy (compared to individuals with bipolar not taking lithium).

3.2 Public and patient involvement

3.2.1 Agenda setting

People with lived experience of bipolar disorder have been involved in the HELIOS-BD project from the very beginning. During the preparation of the funding application, two focus groups (Bipolar Scotland members) and 5 individual meetings with international people with bipolar disorder were conducted to gain insight into the research priorities and concerns of people with lived experience of bipolar disorder. During these discussions, topics of light perception, sleep, lithium and seasonality were explored in relation to bipolar disorder. It was found that these topics were relevant and of interest to people of bipolar disorder, with a consensus that mood changes were significantly influenced by the seasons, and a desire to understand this further. One focus of discussion was the efficacy of lithium at different times of the year, and the differing experiences of people with Type 1 and Type 2 bipolar disorder in relation to treatment, light perception and seasonal sensitivity.

3.2.2 Study design

The HELIOS-BD study design has been shaped by public and patient involvement during initial focus group discussions, study material review by members of Bipolar Scotland, and discussions with the newly-established HELIOS-BD Lived Experience Advisory Panel (LEAP) group following the funding award. Overall, our discussions with people with lived experience of bipolar disorder found people to be agreeable to the proposed study design.

Much of the focus of these discussions fell on Part A of the study, wherein participants attend 2 consecutive overnight stays at a clinical research facility and undergo serial blood sampling and a light exposure experiment. In response to concerns about the burden of sleep studies in relation to work schedules and responsibilities, the number of overnight stays was limited to the absolute minimum required to meet the study primary outcome measures (two nights). Altering light exposure during the study was considered to be an acceptable approach.

Feedback from members of Bipolar Scotland helped to ensure that participant-facing study materials, such as consent forms and Participant Information Sheets, were accessible and clear.

3.2.3 Recruitment

The HELIOS-BD LEAP group will act as ‘research champions’, making the bipolar disorder community in Scotland aware of this project and facilitating the dissemination of information about how to take part, via a social media campaign.

3.2.4 Data collection, analysis and dissemination

HELIOS-BD researchers and the HELIOS-BD LEAP group currently meet bi-monthly to ensure lived experience remains central to the project.

For the remainder of the project timeline, the research team and HELIOS-BD LEAP group will work closely together during the data collection, analysis and dissemination phases of the project. This collaboration will span a range of activities, including: consultation with the LEAP to troubleshoot and overcome relevant issues during data collection; working together to interpret results; conducting a community peer review to discuss study findings ( Liboiron et al., 2018); determining different ways of communicating study results with relevant communities.

3.3 Study duration

The HELIOS-BD study will last for five years in total, with a start date of June 2023. We anticipate that screening and recruitment will begin in December 2023, and study visits will occur until January 2028 (t=54 months). This leaves 6 months for data analysis and dissemination.

3.4 Study design

This is an experimental study with cross-sectional and longitudinal data collection from three participant groups. Over an 18-month period, participants will attend multiple study visits to complete a range of tests, from retinal imaging to electrophysiological recordings and melatonin suppression experiments.

3.4.1 Identification of potential participants

Our overall participant identification strategy represents a close collaboration with Bipolar Scotland, the Scottish Health Research Register (SHARE), the NHS Research Scotland (NRS) Mental Health Network and NRS Primary Care Network, and NHS health boards in Scotland who will act as Participant Identification Centres (PICs). An overview of potential participant identification and recruitment processes is given in Figure 1.

Figure 1. Overview of participant identification and recruitment procedures.

Figure 1.

Abbreviations: BD, bipolar disorder; NRS, NHS Research Scotland; PIS, Participant Information Sheet.

The primary recruitment avenue for both control and bipolar disorder groups will be via SHARE, a database of volunteers who consent to the access and use of their electronic health records to identify them for participation in research. SHARE will send an invitation letter and/or email with a link to the HELIOS-BD website (Participant Information sheet (PIS) available here) to potentially eligible participants, on behalf of the study team. There will also be an option for participants to request a paper copy of the PIS. These potential participants will then be able to contact the research team directly to express an interest. SHARE will also call some potential participants, using their web-based password-protected tracker to record these calls. The study team will be given the password and logs on to see who has been identified as wishing to take part, and to view any notes from the conversation, e.g., holiday dates, alternative number, working hours, etc. The study team will then directly contact those who expressed an interest by phone.

We will also recruit bipolar disorder participants from the NHS mental health services in Scotland via the NRS Mental Health Network. This network facilitates the recruitment of NHS patients into clinical research studies and clinical trials. The Network does this by working closely with NHS clinical teams to publicise studies to patients and clinicians through targeted advertising in clinical areas, and directly to the public. Where possible, the Network works with clinicians to identify potential participants, or pre-screens patient databases and reviews clinical records to create short lists of potential participants for clinical review. The clinical team can then inform these potential participants about the study and gain verbal consent for the NRS Mental Health Network to provide the PIS on behalf of the study team. The NRS Mental Health Network will also distribute the HELIOS-BD study poster to patient-facing locations.

Participants will additionally be recruited via the NRS Primary Care Network. This is a national, Scottish Government Health Directorate-funded network that facilitates eligibly funded research in primary care. Network staff work on behalf of the healthcare team under practice staff supervision. They sign practice confidentially agreements as required. In addition, each member of Network staff holds a current NHS substantive or honorary contract to allow them to carry out these duties. Searches are undertaken at each GP practice and the list generated by the search is screened by a clinician before invitation letters are sent out on behalf of the practice. Letters are sent out via docmail, an approved secure NHS mail service used by the Primary Care Network as standard. Patients are asked to contact the research team if they are interested in participating in the study. The network will recruit participants with bipolar disorder, but also control participants if required.

We will also list Scottish health boards as Participant Identification Centres (PICs), who will be able to identify potential research participants by processing personal data (they will carry out a search of patient record databases and caseloads to identify individuals that meet the studies eligibility criteria) and then send these potential participants a study information letter, with a link to the HELIOS-BD website (‘PIS available here’). These potential participants will then be able to contact the study team directly to express an interest, or to request a paper copy of the PIS if preferred.

Finally, we will recruit participants from the Bipolar Scotland ( www.bipolarscotland.org.uk) and Bipolar Edinburgh ( https://www.bipolaredinburgh.org.uk) membership across Scotland. Bipolar Scotland and Bipolar Edinburgh will help to publicise this study via social media and will send an invitation letter and PIS to their membership on behalf of the study team. Our Lived Experience Advisory Panel from Bipolar Scotland will act as ‘research champions’, making the bipolar disorder community in Scotland aware of this project and facilitating the dissemination of information about how to take part, via a social media campaign. Individuals who have been informed of the study either directly (through invite letter) or indirectly (through advertisement) will be invited to contact the study team via telephone or email for further information and screening.

3.4.2 Screening procedure for recruitment

Potential participants will have an initial screening call with a member of the study team to confirm that they meet the study inclusion criteria and to give them the opportunity to ask further questions about the study. The call will preferably be conducted using the ‘Nearme’ video consulting service on secure NHS Lothian accounts. If a potential participant does not have access to a smartphone or internet connection, the screening call will be conducted via telephone.

If the individual wishes to proceed with participation, personal data (age, sex (as defined by self-report), ethnicity, postcode (for socioeconomic status)) will be collected during this screening call. The researcher will complete a verbal consent form to gain consent from the participant to collect and securely store this demographic and eligibility data, and a copy of the verbal consent form will be sent to the participant. Their contact details will be recorded for study communication purposes and their participation appointment dates will then be booked.

3.4.3 Consenting participants

Consent will be taken from each participant and recorded on a consent form. Participants will be provided with a participant information sheet (PIS) at least 3 days prior to their initial screening telephone call, which will detail in full what they can expect from the study. They will be given an opportunity to discuss the study procedures during the initial consultation (via Nearme or phone), and have any questions answered. A summary of the research project will be provided by the research team member that will cover all elements specified in the PIS and consent form.

At their subsequent baseline study visit with a member of the research team, potential participants will be given the opportunity to ask questions and check their understanding of any points on the consent form before signing. It will be emphasised that the participant may withdraw their consent to participate at any time, without loss of any benefits to which they otherwise would be entitled.

The researcher taking consent will have undergone training in Good Clinical Practice. The principles of the Adults with Incapacity (Scotland) Act 2000 will also be followed. For the purposes of the Act, "incapable" means being unable to act on, make, communicate, understand, or retain the memory of decisions. If there are concerns that a potential participant’s capacity is borderline or likely to fluctuate, they will not be included in the study. All efforts will be made to avoid coercion and consent will be entirely voluntary, with potential participants allowed as much time as they need to decide. Potential participants will not have any identifiable dependent relationship to the research team.

All participants will be informed and will agree to their medical records being inspected by regulatory authorities and representatives of the sponsor(s). The Investigator or delegated member of the research team and the participant will sign and date the Informed Consent Form(s) to confirm that consent has been obtained. All participants will receive a copy of this document and a copy will be filed in the Investigator Site File (ISF) and sent to the participant’s GP.

3.4.4 Participation procedures

An overview of participation timeline and procedures is given in Figure 2.

Figure 2. Overview of participation timeline and study procedures.

Figure 2.

3.4.4.1 Baseline study visit

Participant enrolment and baseline clinical assessment will be conducted in an appointment lasting up to 1 hour. All participants will be invited to attend this appointment face-to-face at the Clinical Research Facility (CRF) (Royal Infirmary of Edinburgh). Participants will be given the option to complete the baseline assessment in-person (at the Clinical Research Facility, CRF, RIE) or online via Near Me.

During this appointment, eligibility criteria will be checked again and individuals will give written consent to participate in the study. Written consent will either be on paper (if the appointment is in-person), or electronically (if the appointment is online). A structured clinical assessment will record:

  • Details of demographics and lifestyle (educational attainment, employment status, socioeconomic status, smoking status (current smoker/non-smoker, ex-smoker, never smoked), substance use, and alcohol use assessed using the Alcohol Use Disorders Identification Test, AUDIT (Saunders et al., 1993))

  • Sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI) ( Buysse et al., 1989) (licence agreement in place 04/03/24)

  • Chronotype assessed using the Munich Chronotype Questionnaire (MCTQ) ( Roenneberg et al., 2003) (copyright license obtained 08/12/23)

  • Global assessment of function (GAF) assessed using the WHODAS 2.0 ( Measuring Health and Disability, 2010; Ustün et al., 2010)

  • Past psychiatric history (including age of onset, number and timing of episodes of depression, hypomania and mania, and a detailed assessment of past and current medication use, including the Retrospective Assessment of the Lithium Response Phenotype (Alda) Scale ( Grof et al., 2002).

3.4.4.2 Part A: Overnight experimental assessments

Two weeks prior to attending for the overnight experimental assessments, participants will be sent an actigraphy wristband and sleep diary, along with clear instructions for use (the actigraph can be preset to start recording when convenient). Daily light exposure and sleep-wake cycles will be monitored in the home setting for 10 days using the diary and wristband, as well as a record of daily caffeine and alcohol use. Participants will be given advice on limiting alcohol use, and on maintaining a regular sleep schedule for the duration of their participation.

In the rare occasion of a last-minute Part A cancellation, the appointment slot will be offered to an enrolled Control participant. In this instance, the actigraphy and sleep diary data will not be collected prior to the Part A overnight visits for that individual, and can be collected at another time point during the individual’s participation. This data is not required to meet the primary study outcomes.

Part A overnight experimental assessments will be conducted between the months of September-April inclusive to avoid the effects of too much light at night during the summer months.

Study Day 1

On Day 1, participants will attend the Clinical Research Facility in Edinburgh from 1700h. On arrival, there will be a check that participants still satisfy the inclusion and exclusion criteria and measurements of blood pressure, heart rate, height and weight will be taken. Participants will then be cannulated for the blood sampling used for melatonin measurements. A 2ml sample of blood will also be taken from the ‘bipolar disorder on Lithium’ group to test for lithium levels. An 8ml sample of blood will be collected and stored long-term for use in future ethically approved studies, including WP1 of the HELIOS-BD programme (wherein our collaborators in Newcastle/Northumbria will conduct retinal organoid research that is part of a separate ethics approval and protocol).

Participants will be required to ingest an eCelsius Performance telemetric temperature pill (BodyCAP, France) to monitor their core body temperature (CBT) throughout the first study night. The temperature-sensing pill is the size of a capsule tablet, does not record any information other than body temperature, and remains intact and will pass within 24–48 hours in the participant’s stool.

Participants will be offered meals as appropriate to the time of day and unlimited decaffeinated liquids. Participants will not be allowed to snack during the hours of blood sampling (19:00-06:00). From arrival at the CRF until lights out, participants will be kept under dim light conditions (<5 lux) until 2200h. During dim-light exposure, participants will not be allowed to use light-emitting devices such as mobile phones, tablets or e-readers. At 2200h, all lights will be turned off and participants will be invited to sleep. Participants can rise and turn on the lights at any time of their choosing from 0600h onwards.

During night 1, CBT will be measured with an ingestible eCelsius telemetric temperature pill, to allow us to schedule the light pulse during the subsequent night in reference to the temperature nadir. If the telemetric pill data cannot be collected (e.g. due to contraindication or data loss) then CBT nadir will be estimated using 12-day sleep diary. Blood sampling from a venous catheter will be performed hourly at night for baseline measurement of melatonin levels (1900h – 0600h). If at any point overnight it is no longer possible to use the cannula to obtain venous blood samples, up to 4 venous blood samples can be obtained via venepuncture. Samples will be centrifuged and blood plasma will be deep frozen until melatonin radioimmunoassay analysis.

Participants will be allowed to leave the Clinical Research Facility the next morning (Study Day 2) before 0900h, returning at 1700hr. Their venous cannula will be removed prior to their departure.

Study Day 2

On Study Day 2, participants will return to the CRF from 1700hr and will be subject to the same conditions as Study Day 1 (meals provided, unlimited decaffeinated liquids, no snacking, bed times and light exposure). Participants will be cannulated on arrival for the blood sampling used for melatonin measurements. During night 2, participants will be free to sleep from 2200h as they wish and are able to, except for the period of nocturnal light exposure for melatonin suppression when they need to stay awake with their eyes open.

Approximately 120 minutes before the CBT nadir, bilateral ocular application of Minims Tropicamide 1.0% will be carried out by a member of the research team to dilate the participant’s pupils. 90 minutes before the estimated CBT nadir, a member of the research team will expose participants to a 30-minute light stimulus. The light exposure will be delivered within a box measuring 100 × 80 × 50 cm. The box is painted white on the inside and contains an LED bulb, covered by a white shade with an aperture in the base. The front side of the box is open. Participants will be requested to keep their hands and head inside the box for 30-minutes, with eyes open throughout.

If the CBT measure is deemed to be inaccurate or unreliable (for example, in the case of data transmitting failure of the device to the receiver) the habitual mid-point of the participant’s sleep will be used as an indicator of the CBT nadir.

Blood sampling will be performed hourly at night to cover a period before and after the light exposure, for measurement of melatonin levels (1900h – 0600h). For the 90 minutes surrounding the light stimulation protocol (30 minutes prior, 30 minutes during, and 30 minutes post), blood samples will be collected at 15-minute intervals. If at any point overnight it is no longer possible to use the cannula to obtain venous blood samples, up to 4 venous blood samples can be obtained via venepuncture. Samples will be centrifuged and blood plasma will be deep frozen until melatonin radioimmunoassay analysis.

If the participant cannot complete the light stimulation protocol at the scheduled time due to an unforeseen issue (e.g. side effects from eye drops), the light stimulation protocol can be attempted/re-attempted within 1 hour of the scheduled time, at the discretion of the research staff, without needing to re-administer eye-drops. If light exposure is commenced but it is not possible to complete the full 30 minutes of exposure, the rest of the protocol procedures (e.g. blood sampling) will still be completed as planned (if possible). Light exposure will not be reattempted once the participant has been exposed to light, even if this is for a short period.

Study Day 3

On Study Day 3, participants can rise and turn on the lights at any time of their choosing from 0600h onwards. Their venous cannula will be removed and participants will be allowed to leave the Clinical Research Facility and go home. Due to the pupil dilation and disrupted sleep period, participants will be advised not to drive on Study Day 3 if they feel their vision has not returned to normal and it is unsafe to drive. Taxi transport will be provided if participants are unable to take public transport home.

After these assessments, all participants will be clinically assessed on the phone or via video call within 3 days to ensure that they have not experienced significant manic or depressive symptoms.

3.4.4.3 Part B: Retinal assessments

Experimental assessments will be conducted at the Colour and EEG laboratories (Dugald Stewart Building, University of Edinburgh). Testing will be completed in two sessions lasting approximately 2-3 hours each: one for colour psychophysics and pupillary responses; the other for visual evoked potentials. Participants will be assessed within a single day (with at least a 1 hour break in between, to avoid fatigue) or in 2 separate sessions, according to their preference. On arrival, there will be a check that participants still satisfy the inclusion and exclusion criteria.

Session 1 - Colour psychophysics and pupillary responses (Colour lab)

Participants will perform the following set of tasks:

1) Trivector test from the Cambridge Colour Test (Metropsis, Cambridge Research Systems, UK): circa 10 minutes (including instructions and some practice). The test measures three thresholds: along the 1) protan (Long-wavelength or L-cone), 2) deutan (Mid-wavelength or M-cone), and 3) tritan (Short-wavelength, or S-cone) axes. This test uses three interleaved adaptive psychophysical staircases to achieve a fast and precise measurement of cone function. It starts with a chromatic contrast at the extreme end of display gamut and subsequently modulates contrast along confusion lines that isolate L, M and S-cone function. Participants detect the orientation of a Landolt C type stimulus (up, down, left or right) embedded with a luminance-variegated background. Their responses control target chromatic contrast, so that the distance from neutral grey (i.e., background chromaticity) decreases for correct responses and increases for incorrect responses. This test has been used in a range of clinical populations (e.g., Parkinson’s disease, optic neuropathy, multiple sclerosis).

2) Contrast sensitivity functions (evaluated using Cambridge Research Systems, UK equipment) will provide a full characterisation of spatial vision driven by luminance and colour. In this test, gratings are displayed in the centre of the screen at 5 different spatial frequencies (range: 0.5 – 6 cycles per degree). Participants are asked to adjust the contrast of the stimulus until it is just barely visible. This should take 25 minutes in total, including instructions and some practice.

3) Suprathreshold just noticeable differences (JNDs) for luminance-defined, red-orange and blue will be measured using custom-made psychophysical procedures implemented on specialist colour vision equipment (CRS, UK). Participants will be presented with two stimuli, one on each side of the fixation cross. One of the two stimuli will be fixed (the standard stimulus; orange or turquoise) while the comparison stimulus will have its properties controlled by an adaptive staircase procedure. Participants will be instructed to report which of these two clearly visible (i.e., suprathreshold) stimuli is 1) brighter or 2) redder (for orange standard) or bluer (for turquoise standard). Manipulating the contrast of the comparison patch relative to the standard patch (which remains the same) allows for a precise measurement of a Just Noticeable Difference (JND) – the difference in luminance or chromatic contrast needed to make the two stimuli reliably different in appearance. The standard patch will be set to an intermediate hue (orange or turquoise) and at a luminance level brighter than the background, to mimic the appearance of disks in Lanthony’s D-15d test in which bipolar disorder participants have been reported to exhibit performance deficits ( Fernandes et al., 2017). Administration takes ~20 minutes, including instructions and practice.

4) Pupil responses to light stimuli will be captured using a pupilometer capable of melanopsin-selective stimulation (OculoWise, Switzerland). Participants will first undergo 10 minutes dark adaptation before completing a post-illumination pupil response protocol, which measures pupil size in response to narrowband irradiance-matched red and blue light pulses. Similar protocols will then be administered using light pulses that (using the method of silent substitution) selectively target the cone-mediated luminance mechanism, and melanopsin. The resulting pupil responses are expected to provide a robust measure of increased retinal light sensitivity in bipolar disorder participants (administration ~45 minutes, including instructions and practice).

Session 2 - Visual evoked potentials (VEPs; EEG laboratory)

Participants will be able to take part in the EEG session either in the same afternoon (if they performed Session 1 in the morning) or on a separate day, depending on their preference.

Upon arrival, the EEG equipment will be set up and the electrodes positioned on the participant’s scalp. A BioSemi ActiveTwo (BioSemi, Netherlands) 64-electrode system will be used. Hypoallergenic electroconductive gel will be used to establish contact between the scalp and the electrode. Gel ensures a stable signal over a relatively long period of time.

We will measure VEPs elicited by contrast modulated patterns defined along the three retino-geniculate mechanisms (achromatic and chromatic). More specifically, pattern-onset and steady-state VEPs will be measured at multiple levels of contrast for uniform unipolar Gabor patches defined by increments and decrements along the achromatic, reddish-greenish and bluish yellowish axes. The experimental protocol will last for 1 hour.

EEG set up and removal will take approximately 60 minutes. An additional half-hour will be added to testing time to allow for participants to wash their hair in the laboratory’s hair-washing facilities after the data collection has ended, in order to remove the electroconductive gel.

3.4.4.4 Part C: Retinal imaging

Part C involves three study visits to image the microstructure of the retina and to investigate longitudinal retinal changes over an 18 month period. The schedule for Part C study visits is 0-, 9- and 18-month time-points. Each imaging session will last about up to 1.5 hours.

Imaging will be conducted at the Edinburgh Imaging facility in the Queen’s Medical Research Institute on the BioQuarter Little France campus. Retinal scanning is non-invasive and a completely safe method of obtaining pictures of the retina. Images are fast to acquire, and non-contact, non-invasive and require only simple chin-rest positioning. Pupil dilation is not required for any of the imaging.

A trained member of the research team will image both eyes of a participant using:

  • 1.

    Fundus camera photograph: A fundus camera generates a 2D, high resolution image showing the optic disc, macula and blood vessels, and permits analysis of these anatomical features.

  • 2.

    Ultra-widefield scanning laser ophthalmoscopy: An ultra-widefield scanning laser ophthalmoscope (UWF-SLO) captures more of the retina in one go ( ~80%) and facilitates the study features and changes in the periphery (e.g. prevalence of drusen, and vascular abnormalities and integrity), though at the sacrifice of a lower resolution for an increase in image field.

  • 3.

    Optical coherence tomography (OCT): OCT images the retinal nerve fibre layer (RNFL) and inner layers of the retina.

  • 4.

    OCT Angiography (OCT-A): OCT-A reveals the very small capillary level vessels in the retina which are not possible to image in any other way.

  • 5.

    Optical biometry: Optical biometry yields the eye’s axial length - i.e. the distance from front to the back - a vital measure used to account for differences in individuals’ eyes and an important metric for the evaluation of retinal biomarkers.

  • 6.

    Automated perimetry: Automated perimetry tests a participant’s visual field. The participant sits in front of the machine and presses a button when they see the presentation of a white light stimulus in various locations of their visual field. This will reveal any functional changes over time which can then be compared to any structural changes detect with the other imaging techniques.

  • 7.

    Autorefraction: Autorefraction measures a participant’s refractive error (i.e. how short- or long-sighted they are).

Modes 1–4 of retinal scanning provide different but highly informative images of the back of the eye. Anonymised image data will be analysed by the relevant members of the research team in the Centre for Clinical Brain Sciences at the University of Edinburgh. There is a small risk that incidental findings may be identified on the retinal images which may require further investigation. We anticipate the rate of significant or urgent findings to be <1%. Each participant will be told of this risk, as well as it being stated on the participant information sheet. Should we observe unusual signs in the images that might signs of eye problems, anonymised images will be reviewed by the ophthalmologist on our team for checking of incidental findings. If we were to observe any such findings then an appropriate member of the study team would discuss this with the participant and inform their GP so that appropriate further tests and treatments could be arranged as necessary.

3.5 Data collection/participation windows

Baseline, Part B and Part C study visits and data collection will take place throughout the year.

Part A participant appointments and data collection will take place between the months of September and April (inclusive). Restricting data collection to these months avoids days with extremely long photoperiods (summer months) where night-time is limited or absent.

In the event of an abandoned study visit where a participant is unable to complete all protocol tasks, they will be invited back to complete the appointment at a later date if deemed appropriate by the study team.

The first screening and study visits (December 2023–March 2024) served as a pilot phase to fine-tune the assessments and/or their delivery. Protocol amendments were introduced where necessary

3.6 Study population

3.6.1 Sample size calculation

This study will assess 180 participants:

  • n=60 with bipolar disorder and currently on lithium therapy

  • n=60 with bipolar disorder and not taking lithium

  • n=60 healthy controls with no history of mental illness and no first-degree family history of mental illness

The required sample size for this study is calculated from melatonin measures relevant to Part A. This sample size is sufficient for both Part B and Part C of the project (see below). Sex and gender differences were not taken into consideration in study design or sample size calculations because there is no conclusive evidence of sex or gender differences in the primary study outcome measures.

3.6.1.1 Part A Sample Size Calculation

Our subjects of interest are BD patients versus controls, with the BD group sub-divided into two groups: one where BD subjects are on lithium therapy and another where BD subjects are not taking lithium. Based on previous reports of light-induced melatonin suppression in BD ( Hallam et al., 2009) we expect a difference of approximately 40–50% (Cohen’s d effect size 0.5–0.6) between the BD lithium group and the BD non-lithium group. As such, for 80% power with an alpha of 5%, we will need 42 participants in each of the three groups. Allowing for incomplete data collection in up 30% of participants, this means that we will recruit 60 participants in each group.

3.6.1.2 Part B Sample Size Calculation

With this sample size (N=180 participants across three groups), a two-sided between-subjects t-test at 80% power with an alpha level of 0.05 will be able to reliably detect an effect size of d=>0.52, equivalent to a difference of 0.52 of a standard deviation (i.e., medium effect size). Comparably, a between-subject ANOVA with three groups would be able to detect an effect size of f=>0.23. For a clinical study of this kind, this represents a very high level of sensitivity. As a minimum, it will allow us to provide a more definitive characterisation of the observed phenomena than previous studies in this field. As a comparison, studies with groups of 20 participants, which are common in the existing literature, are capable of detecting an effect of d=>0.9 (two groups) or f=>0.41 (three groups), which are large effect sizes.

3.6.1.3 Part C Sample Size Calculation

Part C is an exploratory study and is configured as the first step into investigating what sort of longitudinal retinal changes can be expected in a BD population. It is therefore difficult to estimate measurable effect size and very hard to predict which features will be discovered as relevant by computational approaches. However, the results of our analysis will be vital to informing future work. The samples size for Part C are thus informed by those of Part A and B, and an n=60 per group is used as an achievable target for imaging a sufficient number of participants for developing, testing and assessing our methods.

3.6.2 Inclusion criteria

All participants

Study participants must be adults ≥ 18 years old with capacity to give informed consent and to comply with the study design. All participants must be living in Scotland, be registered with a GP within NHS Scotland, and must have fluency in written or spoken English.

BD Lithium participant group

Participants in the ‘BD Lithium’ group must have a diagnosis of bipolar disorder according to DSM V criteria, confirmed with the Structured Clinical Interview for DSM5 (SCID) with at least one previous manic or two previous hypomanic episodes. Where possible, the diagnosis of bipolar disorder will be corroborated using clinical notes or records. Participants in the ‘BD Lithium’ group must be clinically euthymic with no episodes of depression, hypomania or mania for at least three months prior to enrolment. Participants will be asked to inform the study team of any mood episodes they have developed in the three months prior to any study appointment. Affected appointments will be rescheduled once the participant has been euthymic for 3 months. They must be on a stable lithium medication regimen for at least six months prior to study participation.

BD Non-Lithium participant group

Participants in the ‘BD Non-Lithium’ group must have a diagnosis of bipolar disorder according to DSM V criteria, confirmed with the Structured Clinical Interview for DSM5 (SCID) with at least one previous manic or two previous hypomanic episodes. Where possible, the diagnosis of bipolar disorder will be corroborated using clinical notes or records. Participants in the ‘BD Non-Lithium’ group must be clinically euthymic with no episodes of depression, hypomania or mania for at least three months prior to enrolment. Participants will be asked to inform the study team of any mood episodes they have developed in the three months prior to any study appointment. Affected appointments will be rescheduled once the participant has been euthymic for 3 months.

Participants in the ‘BD Non-Lithium’ group must not be currently taking lithium, and must have no lithium use for at least six months prior to study participation.

3.6.3 Exclusion criteria

All participants

Exclusion criteria for all participants includes the inability to give consent and inability to comply with study design. Individuals cannot participate in the study if they are currently enrolled in an interventional research study. Medical exclusion criteria include: pregnancy, diagnosis of sleep or circadian disorders; claustrophobia; epilepsy; blindness or significant visual impairments; existing eye disease such as glaucoma or age-related macular degeneration; previous surgery on the retina; use of melatonin or melatonin-suppressing medications (such as beta-blockers). Other significant medical conditions which, in the investigator’s opinion, could skew or confound data from investigations (e.g. neurological conditions such as multiple sclerosis) will be assessed on a case-by-case basis and excluded if necessary. Individuals with harmful use of or dependence on psychoactive substances, including alcohol (as per ICD-10) will not be eligible to participate. Due to their impacts on circadian rhythmicity, current shift work (variable day shift pattern or night shifts) and trans-meridian travel within the preceding month exclude individuals from participation.

Control participant group

Participants in the control group must not have recent history of any psychiatric illness or psychotropic medication use (within the past 12 months for psychiatric condition), or previous history of severe mental illness (psychosis, severe depression, psychiatric hospital admission). First-degree family history of psychosis or severe mood disorder excludes individuals from participation.

3.6.4 Participation window

The amount of time each participant will be actively participating in the study will vary depending on how closely together they wish to complete all parts. The anticipated minimum amount of time required will be 20 months, from receipt of study invite to completion of all assessments.

3.6.5 Payment of Study Participants

All enrolled study participants will be reimbursed for their participation time, costed at £15 per hour (estimated 38 hours total). If a participant withdraws from the study, they will be paid for the time they have completed up until that point. Travel (public transport, fuel, parking) and childcare costs will additionally be reimbursed. If a participant completes all of the assessments, they will be reimbursed up to a maximum of £750 including expenses. Payments will be made via bank transfer using University of Edinburgh standard procedure.

3.6.6 Withdrawal of Study Participants

Participants will be informed via the PIS that their participation is entirely voluntary and that they are free to withdraw from the study at any time. Information already collected will still be used when preparing the results of the study, unless the participant tells us they don’t want their information to be used in this way. Once the study has finished and the data have been analysed for publication, participants will no longer be able to withdraw their information. If a participant lost capacity during the study, it would not be appropriate to continue the study data collection as ongoing consent would be required. Data already collected would still be used. To safeguard rights, minimal personally identifiable information will be collected.

3.6.7 Risk assessment and distress procedure

The research team will have regular contact with participants in this study. If any significant issues arise, all participants will be informed by phone and letter. This includes both self-reported issues and issues that may arise from the tests conducted, or data collected. Some participants may find some questions in the questionnaires sensitive in nature (questions about their mental health past and present). Where there is any clinical risk to the participant (for example the disclosure of suicidal thoughts) the interviewing psychiatrist or research team member will ask for consent to contact the patient’s GP and treating community mental health team (if they have one), so that appropriate monitoring and follow-up can be arranged.

3.7 Study assessments

Table 1 details provides an overview of all study assessments and time points at which they will occur. Further details of the assessments are as follows:

Table 1. Study Assessment measures and collection time points.

Abbreviations: AUDIT, Alcohol Use Disorders Identification Test; DSM-V, Diagnostic and Statistical Manual of Mental Disorders 5 th Edition; EEG, electroencephalography; OCT, Optical Coherence Tomography; OCT-A, Optical Coherence Tomography Angiography; m-SPAQ, Modified Seasonal Pattern Assessment Questionnaire; MCTQ, Munich Chronotype Questionnaire; VEPs, Visual Evoked Potentials.

Assessment Screening
Call
Baseline
Clinical
Assessment
Part A Part B Part C
1. Collection of contact details graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
2. Verbal informed consent graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
3. Assessment of Eligibility Criteria graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg
4. Written informed consent graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
5. Demographic and lifestyle data graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
6. Alcohol Use Disorders Identification Test, AUDIT graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
7. Past psychiatric history (including medical notes
screening if possible)
graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
8. Assessment of past and current medication use graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
9. Retrospective Assessment of the Lithium
Response Phenotype (Alda) Scale
graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
10. Pittsburgh Sleep Quality Index (PSQI)
questionnaire
graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
11. Munich Chronotype Questionnaire (MCTQ) graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
12. Modified Seasonal Pattern Assessment
Questionnaire (m-SPAQ)
graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
13. WHODAS 2.0 Questionnaire graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
14. Sleep Diary graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
15. 24-hour actigraphy graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
16. Measurement of light exposure levels graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
17. Pregnancy test (if applicable) graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
18. Heart rate, blood pressure, height and weight
measurements
graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
19. Cannulation graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
20. Blood sample collection graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
21. Ingestion of eCelsuis telemetric temperature pill graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
22. Overnight Sleep Study Protocol graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
23. Bilateral ocular application of pupil dilator
medication Minims Tropicamide 1.0%
graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
24. 30 minute light stimulus graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
25. Follow-up wellbeing call graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
26. Cambridge Colour test graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
27. Contrast sensitivity test graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
28. Colour discrimination test (Just noticible differences) graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
29. Pupillometry graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
30. Electroencephalography (EEG)/ Visually evoked potentials (VEPs) graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg
31. Fundus camera photograph graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg
32. Ultra-widefield scanning laser ophthalmoscopy graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg
33. Optical coherence tomography (OCT) graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg
34. OCT Angiography (OCT-A) graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg
35. Optical Biometry graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg
36. Automated perimetry graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg
37. Autorefraction graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0003.jpg graphic file with name wellcomeopenres-9-25555-g0002.jpg

3.7.1.1 Screening Appointment

1. Collection of contact details: Contact details will be collected during the initial screening appointment to allow for further communications between the research team and potential participants.

2. Verbal informed consent: Potential participants will provide verbal informed consent for the purposes of the screening call data collection.

3. Assessment of eligibility criteria: Potential participants will be screened for eligibility criteria at the initial screening day and again at baseline study visit. This will include a structured diagnostic assessment for bipolar disorder at the screening appointment.

3.7.1.2 Baseline study visit

4. Written informed consent: Potential participants who meet the study eligibility criteria will provide written informed consent during enrolment to the study at baseline study visit.

5 Demographic and lifestyle data (self-reported): Age; self-reported sex; gender identity, ethnicity; educational attainment; employment status; socioeconomic status measured using the Townsend Deprivation Index; smoking status.

6. Alcohol Use Disorders Identification Test, AUDIT (Saunders et al., 1993): Validated questionnaire to assess alcohol use.

7. Past psychiatric history: Data including age of onset, number and timing of episodes of depression, hypomania and mania will be collected. This is to gain a full understanding of the participant’s clinical history.

8. Assessment of past and present medication use: To be used as variates in future analyses.

9. Retrospective Assessment of the Lithium Response Phenotype (Alda) Scale ( Grof et al., 2002): Validated questionnaire to retrospectively assess lithium response phenotypes in bipolar disorder participants.

10. Pittsburgh Sleep Quality Index (PSQI) ( Buysse et al., 1989): Validated questionnaire which assesses sleep quality and sleep disturbance.

11. Munich Chronotype Questionnaire (MCTQ) ( Roenneberg et al., 2003): Validated questionnaire to assess chronotype, collecting information about sleep and wake under natural conditions, including sleep and wake timings.

12. Modified Seasonal Pattern Assessment Questionnaire (m-SPAQ) (modified from Rosenthal et al., 1984): Validated questionnaire to assess impact of seasons on mood and day-to-day life. The questionnaire is modified with the addition of several questions relating to bipolar disorder symptoms and seasonality, the results of which will not be aggregated into the SPAQ scoring system.

13. WHODAS 2.0 Questionnaire ( Measuring Health and Disability, 2010; Ustün et al., 2010): Validated assessment instrument for health and disability, covering six domains of functioning: cognition, mobility, self-care, getting along, life activities, and participation.

14. 12-days of Sleep Diary: For the 10 days prior to the overnight CRF study, and for the duration (2 days) of the overnight CRF study, participants will be required to complete a sleep diary to collect data on their sleep and wake timings.

15. 12-days of 24-hour actigraphy: For the 10 days prior to the overnight CRF Study, and for the duration (2 days) of the overnight CRF study, participants will be required to wear a wristband actigraphy device (Axivity, UK) to measure their wake and sleep rhythms and wake activity levels.

16. 12-days of daily light exposure levels (including daylight exposure on first study day): For the 10 days prior to the overnight CRF Study, and for the duration (2 days) of the overnight CRF study, estimates of light exposure will be derived from the AX3 actigraphy device (Axivity, UK) and ActLumus light logger (Condor Instruments, Brazil) respectively.

3.7.1.3 Part A

17. Pregnancy test: Upon arrival to the Part A appointment, participants of childbearing potential (between the stages of menarche and menopause) will be required to complete a pregnancy test to confirm that they are not pregnant prior to their ingestion of the telemetric pill.

18. Heart rate, blood pressure, height and weight measurement

19. Cannulation: Venous cannulation of hand or arm for blood sampling over the two nights.

20. Blood sample collection: A maximum of 31 blood samples (approximately 60mls total) will be taken over the course of the overnight stay:

  • 1 sample: for lithium level testing (2mls) (only BD on Lithium group)

  • 1 sample: for retinal organoid research (Helios-BD Work package 1) (8mls, EDTA Tube), if the participant has consented to their blood samples being used in future ethically approved studies

  • 12 samples: twelve blood samples (2.5mls each) taken at hourly intervals between the hours of 7pm and 6am inclusive on Part A Study Day 1

  • 17 samples: twelve blood samples (2.5mls each) taken at hourly intervals between the hours of 7pm and 6am inclusive on Part A Study Day 2. An additional five blood samples will be taken at 15 minute intervals around the light stimulation protocol (30 minutes prior, 30 minutes during, 30 minutes after).

21. Ingestion of eCelsius telemetric temperature pill: To measure core body temperature over 10 hours on the night of Study Night 1 for calculation of core body temperature nadir.

22. Overnight Sleep Study Protocol: Participants will be required to complete 2 sequential overnight stays at the Clinical Research Facility, Royal Infirmary of Edinburgh. During the Overnight stay, participants will be exposed to dim light conditions (<5 lux) from arrival until 2200h, and dark conditions between the hours of 2200h and 0600h.

23. Bilateral ocular application of pupil dilator medication Minims Tropicamide 1.0%: Application of pupil dilator solution will take place on Study Day 2 approximately 30 minutes prior to the light stimulation protocol

24. 30 minute light pulse: Participants will be exposed to a 30 minute light pulse on Study Day 2. The light stimulation will be delivered 90 minutes prior to the estimated core body temperature nadir.

25. Follow-up wellbeing call: For participant wellbeing to ensure no experiences of significant manic or depressive symptoms occurred due to the study protocol. The follow-up assessment will consist of a telephone call from the clinical research fellow on the team within 3 days of the completion of Study Day 2.

3.7.1.3 Part B

26. Cone-isolating chromatic thresholds, measured using the Cambridge Colour Test. Participants observe Landolt Cs and indicate their orientation. Their responses feed into a staircase that controls stimulus contrast until a threshold is accurately measured.

27. Contrast sensitivity functions. Participants observe gratings of different spatial orientations and indicate their orientation. Their responses feed into a staircase that controls stimulus contrast until a threshold is accurately measured.

28. Just noticeable differences for colour and luminance-defined stimuli (blue, orange and luminance-defined). Participants observe two patches and indicate which one is brighter, redder or bluer. Their responses feed into a staircase that controls stimulus contrast until a threshold is accurately measured.

29. Pupillary responses. Participants are presented with lights that differentially stimulate melanopsin and chromatic pathways and their pupillary response is measured using a RetinaWise device from Oculowise (Switzerland).

30. Visual evoked potentials to spatiochromatically modulated stimuli. Participants will observe a series of bipolar Gabor patches defined along blue-yellow, red-green or achromatic dimensions at several levels of contrast - from low contrast to contrast matching the maximum achievable chromatic modulation within the gamut of our screen. To control attention, participants will be asked to respond to a rare orientation oddball Gabor stimulus, whilst refraining from responding to all other stimuli.

3.7.1.5 Part C

31. Fundus camera photograph. A fundus camera generates a 2D, high resolution image showing the optic disc, macula and blood vessels, and permits analysis of these anatomical features.

32. Ultra-widefield scanning laser ophthalmoscopy. An ultra-widefield scanning laser ophthalmoscope (UWF-SLO) captures 80% of the retina in an image.

33. Optical coherence tomography (OCT). OCT images the retinal nerve fibre layers (RNFL) and inner layers of the retina.

34. OCT Angiography (OCT-A). OCT-A reveals the very small capillary level vessels in the retina which are not possible to image in any other way.

35. Optical biometry. Optical biometry yields the eye’s axial length - i.e. the distance from front to the back - a vital measure used to account for differences in individuals’ eyes and an important metric for the evaluation of retinal biomarkers.

36. Automated perimetry. Automated perimetry tests a participant’s visual field.

37. Autorefraction. Autorefraction measures a participant’s refractive error (i.e. how short- or long-sighted they are).

3.7.2 Storage and analysis of samples

Blood samples will be collected as part of the Part A protocol detailed in Section 3.2.4. A maximum of 31 blood samples will be collected in total as part of the study protocol. Control and BD Non-Lithium groups will have 30 samples collected. The ‘bipolar disorder on lithium’ group will have an additional sample collected to test lithium levels.

Sample collection

In the first instance, as noted above, one 2ml blood sample (‘bipolar disorder on lithium’ group only) and one 8ml blood sample will be taken during Part A. The 2ml sample will be used for lithium level analysis, and will be sent immediately for processing by the laboratory at the Royal Infirmary of Edinburgh. The 8ml sample will be processed and stored long-term at -80 degrees in University of Edinburgh facilities (The Institute of Genetics and Cancer, Western General Hospital) until use in future ethically approved research.

As described above, a total of 29 blood samples will be collected between the hours of 7pm and 6am across both Part A study nights for melatonin level analysis.

Sample storage

Blood samples for melatonin analysis will be centrifuged for plasma extraction and stored in freezers at -80C in the Clinical Research Facility, Royal Infirmary of Edinburgh. Samples will be stored according to the participant (i.e. all samples from one participant will be stored together in 1 box).

Blood samples for long-term storage (and future use in ethically approved studies) will be stored long-term at -80 degrees in University of Edinburgh facilities (The Institute of Genetics and Cancer, Western General Hospital) until use.

Sample processing

1 sample for lithium level analysis will be processed by the biochemistry laboratory at Royal Infirmary of Edinburgh. 1 sample for future ethically approved research (e.g. retinal organoid work (HELIOS-BD Workstream 1) which will be processed by our collaborators Lyle and Hilgen in Newcastle/Northumbria, subject to approvals). 29 samples for melatonin level analysis will be processed and analysed by NovoLytix GmbH, Switzerland. Samples will be analysed in patient batches to control for assay variance. Surplus sample from the analysis process will be destroyed.

3.8 Data collection

3.8.1 Source data documentation

Source data is defined as all information in original records and certified copies of original records or clinical findings, observations, or other activities in a clinical study necessary for the reconstruction and evaluation of the study. Source data are contained in source documents. Source documents are original documents, data and records where source data are recorded for the first time.

3.8.1.1 Paper source documents

•     Consent forms

•     Sleep diary

3.8.1.2 Digital source documents

•     Consent form

•     Electronic Case Report Form - includes procedural checklists and the following data collection instruments:

  • Personal data and contact details

  • Screening data (inclusion/exclusion criteria)

  • Retrospective Assessment of the Lithium Response Phenotype (Alda) Scale score (standardised questionnaire of lithium response phenotype)

  • Alcohol Use Disorders Identification Test (AUDIT) score (standardised questionnaire of alcohol use)

  • Lifestyle information (standardised questionnaire)

  • Past psychiatric history (standardised questionnaire)

  • Medication history (standardised questionnaire)

  • Pittsburgh Sleep Quality Index (PSQI) score (standardised questionnaire of sleep quality)

  • Munich Chronotype Questionnaire (MCTQ) (standardised questionnaire of chronotype)

  • Modified Seasonal Pattern Assessment Questionnaire (m-SPAQ) (standardised questionnaire of seasonality)

  • WHODAS 2.0 Questionnaire score (standardised questionnaire of health and disability)

•     Blood sample analysis (melatonin levels)

•     Actigraphy data (electronic data collection) for 12 days prior to & including overnight CRF stays

•     Ambient light level data (electronic data collection) for 12 days prior to & including overnight CRF stays

•     Core Body Temperature (electronic data collection)

•     Psychophysical data: all psychophysical result files will contain single trial data indicating response accuracy at each stimulus level. Data will be stored as .txt files, to ensure compatibility.

•     Pupilometry: pupil size will be digitally recorded for each light exposure setting and stored in an open-source digital format.

•     Electroencephalography: Data will be recorded in Biosemi format but processed and stored using the default data format of the EEGlab toolbox for Matlab, which is a gold standard in digital EEG data processing.

3.8.2 Case report forms

The Case Report Forms are electronic and hosted on the Research Electronic Data Capture (REDCap) server software ( https://www.project-redcap.org/; RRID:SCR_003445) ( Harris et al., 2009; Harris et al., 2019). The REDCap software is accessed via a web application which allows users to enter and store data in a secure and intuitive user-friendly system. It is used around the world to securely gather research data.

REDCap server software will be accessed using internet browsers on local University of Edinburgh network computers based in Kennedy Tower, University of Edinburgh laptops, remotely via the University of Edinburgh VPN and NHS Lothian computers located at the Clinical Research Facility, Royal Infirmary of Edinburgh. Only members of the research team will be able to register for a password-protected REDCap user account and have access to the study project on the server. Data will be extracted from the electronic CRFs as password-protected, encrypted excel spreadsheets, which will be stored on the University of Edinburgh DataStore, accessed via University of Edinburgh network computers based in the Division of Psychiatry, Kennedy Tower, Royal Edinburgh Hospital (University of Edinburgh).

3.9 Data management

3.9.1 Data storage and access

3.9.1.1 Paper data

All identifiable paper records (e.g. signed consent forms) will be stored in a locked filing cabinet in a locked office at the Kennedy Tower, Royal Edinburgh Hospital (University of Edinburgh). Only the research team members will have access to this, which includes investigators and collaborating groups who have been approved by the study investigators. University of Edinburgh policy regarding data management will be followed at all times ( https://www.ed.ac.uk/information-services/about/policies-and-regulations/research-data-policy). Following completion of the research project, identifiable paper records will be destroyed after 12 months.

3.9.1.2 Digital data

Screening & baseline visit

Digital identifiable data will be stored on secure REDCap server software and will be accessible for the duration of the study. The REDCap instance used for this study is run by Clinical Surgery, University of Edinburgh within the University of Edinburgh Virtual Machine architecture. It is physically secured (servers are physically located at the King’s Buildings campus, The University of Edinburgh, West Mains Road, Edinburgh, EH9 3JW, UK). All transmission and storage of web-based information by this online system is encrypted and was designed to be compliant with HIPAA-Security Guidelines.

Part A

Digital data from the eCelsius telemetric pill will be transmitted wirelessly to the eCelsius monitor in the CRF, and data from this will then be securely downloaded from the eCelsius monitor to the study computer at the Clinical Research Facility, via a direct USB connection. This data will be stored in a .csv spreadsheet, which will in turn be uploaded to the participant’s corresponding REDCap electronic CRF and downloaded to the University of Edinburgh study DataStore (controlled by Information Services at University of Edinburgh). Only authorised members of the research team will have access to the data store.

Digital data from the ActLumus light logger will be securely downloaded to a study computer at the Clinical Research Facility, via a direct USB connection. This data will be stored in a .csv spreadsheet, which will in turn be uploaded to the participant’s corresponding REDCap electronic CRF.

The NHS Lothian medical records of enrolled participants with bipolar disorder will be accessed by the study team to access any information relevant to the study, i.e., that entered at the Clinical Research facility and lithium levels, and then entered into the participant’s REDCap electronic CRF and downloaded to the study DataStore.

Digital data from the AX3 actigraph will be securely downloaded to a University of Edinburgh secure server, via a direct USB connection. This data will be stored in a .cwa file on the study DataStore.

After completion of each participant’s participation in the study, their electronic CRF data will be exported from the REDCap server and fileswithin an encrypted password protected folder on the study DataStore. Upon study completion all data stored using REDCap will therefore have been exported for processing and analysis purposes. All data will be deleted from REDCap 1 year after study completion.

Part B

Digital data from psychometric testing and EEG will be stored electronically in pseudonymised form in a secure folder on DataStore (controlled by Information Services at University of Edinburgh). Only authorized members of the research team will have access.

Part C

Digital data from retinal imaging will be stored electronically in pseudonymised form in a secure folder on DataStore (controlled by Information Services at University of Edinburgh). Only authorized members of the research team will have access.

All study data

Data held on the DataStore will be pseudonymised and the principles of data minimisation will always be followed. Only members of the research team will be able to access the data held on the DataStore, using a secure username and password. Any data which includes personal or identifiable information will additionally be encrypted and password protected.

Data .csv files will be accompanied by meta-data prepared in accordance with UK Data Service and Data Documentation Initiative guidelines. Documentation will include: a data dictionary (.csv file with rows for each variable and columns for: variable label, variable description, variable response scale codes, including missing data codes); a technical report that includes further background information on each variable (organised according to scales and subscales), including processing and further references; a study protocol detailing study design and data collection, with copies of all assessments and questionnaires annotated with variable labels included as appendices.

Personal data will be stored for 15 years after study completion on the University of Edinburgh DataVault. For one year following study completion, data will be held in pseudonymised format. After deletion of identifiable data (one year after study completion), the study dataset will effectively become anonymised. Anonymised digital data will be kept for a period of 14 years after the deletion of identifiable data.

No data will be shared out with the research team without explicit participant consent via the participant consent form. Anonymised data will be made available for download in line with open access principles. Anonymised data will be available for download via an Open Science Framework (OSF) project ( osf.io). This data will be available to the wider research community no later than 1 year after the completion of the project.

We will ensure published data (i.e. in academic manuscripts) does not contain any information that could disclose participant identity. Published results will be a descriptive analysis of aggregate results.

3.9.1.3 Blood sample data

For the melatonin level analysis, the samples will be sent from University of Edinburgh to NovoLytiX GmbH (CH-4108 Witterswil) and then extracted and measured with the NovoLytiX Melatonin RIA (RK-MEL2). They will be sent in a pseudonymised format, with the only identifier being the participant ID number. The results from this analysis will be entered into the Excel files sent in advance by a member of the research team to NovoLytiX GmbH, and subsequently sent back to the research team after completion of each batch of measurements. The raw data are archived anonymously at NovoLytiX GmbH and can be accessed by the principal investigators or other authorised third parties at any time during office hours (after prior registration).

For the lithium level analysis (BD on Lithium group only), results will be stored on the NHS TRAK database and will be linked to the participant’s CHI number. Only NHS staff will have access to these data.

3.9.2 Transfer of data

No data will be shared without explicit participant consent via the participant consent form. Participants will be asked for their GP and psychiatrist’s name, and for consent to inform them that they are taking part in the study, and of any notifiable results. This information will be posted or emailed securely to the GP.

3.9.3 Data controller

The joint data controllers are the University of Edinburgh and NHS Lothian.

3.9.4 Data breaches

Any data breaches will be reported to the University of Edinburgh ( dpo@ed.ac.uk) and NHS Lothian ( Lothian.DPO@nhslothian.scot.nhs.uk) Data Protection Officers who will onward report to the relevant authority according to the appropriate timelines if required.

3.10 Outcome measures

3.10.1 Primary outcome measures

3.10.1.1 Part A

Difference in absolute change in plasma melatonin levels in response to light stimulation protocol between the 3 study groups.

3.10.1.2 Part B

Difference in pupillometry, visual evoked potential, and chromatic discrimination/detection measures between the 3 study groups.

3.10.1.3 Part C

Retinal structure differences between the 3 groups assessed over time

3.10.2 Secondary outcome measures

3.10.2.1 Part A

To determine absolute differences in the following measures between the 3 study groups:

  • ALDA scale (Bipolar Disorder groups only)

  • PSQI total score for sleep quality

  • MCTQ total score for chronotype

  • MEQ total score for chronotype

  • WHODAS 2.0 total score for global function

  • m-SPAQ total score for seasonal sensitivity

3.10.2.2 Part B

Correlation of primary outcome measures with other, non-retinal measures acquired in the study (e.g. questionnaires, medical history), as well as with each other.

3.10.2.3 Part C

Secondary outcomes include cross-sectional and longitudinal differences in retinal vascular metrics; retinal layer thickness; small vessel metrics; eye biometrics; visual field metrics. These outcomes will be correlated with other, non-retinal measures acquired in the study.

3.11 Statistical analysis

3.11.1 Proposed analyses

3.11.1.1 Part A analyses

We will compute the area under the curve for the melatonin profile using the trapezoidal method and also compute the percentage difference between the healthy control group and the BD lithium therapy group, as well as between the healthy control group and the BD non-lithium treatment group. We will then use one-way ANOVA (or Kruskal-Wallis) with post-hoc analyses (Tukey) across the three groups, as well as undertaking general linear model analyses controlling for potential confounding variables such as age, sex, ethnicity, educational attainment, employment status, socioeconomic status, smoking status, alcohol use, sleep quality, chronotype, psychiatric history, medication use and score on the Alda lithium response scale. 

3.11.1.2 Part B analyses

Statistical analyses for the various measures (pupillary response, colour perception, spatiochromatic processing, visual evoked potentials) across the three groups will be performed using linear mixed effect models with healthy control group set as the baseline (i.e., zero) level for all the comparisons. Models will also be evaluated for the contribution of confounding factors, including age, sex, ethnicity, educational attainment, employment status, socioeconomic status, smoking status, alcohol use, sleep quality, chronotype, psychiatric history and medication use and score on the Alda lithium response scale.

3.11.1.3 Part C analyses

We will test the hypothesis that people with BD have significant differences in structural and functional measures of the retina and in the trajectory of change compared to controls. Additionally, we will assess whether individuals with BD who are taking lithium have an attenuated trajectory of change compared to those with BD on other medications. Student’s t-test and generalised estimation equations will be used to examine differences in retinal measures and psychophysical thresholds between the three participant groups. Spearman’s rank correlation coefficient will be used to investigate associations of retinal measures and psychophysical thresholds with other key parameters from the study data, including confounding demographic and clinical factors. Trajectory analysis will be used to assess changes in retinal parameters and psychophysical thresholds over time and how effective this approach is at stratifying participants.

3.12 Dissemination plan

The results of the HELIOS-BD study will be written up for publication in relevant scientific journals. Participants will receive a results summary letter once the study results are available, detailing the findings of the study and once again thanking them for their participation. Results from the study will additionally be summarised on the study website ( www.heliosbd.com).

3.13 Adverse events

Participants will be encouraged to contact the research team at any time should they experience any problems during or following their participation. All adverse events and adverse reactions will be recorded using the appropriate ‘ Adverse Event or adverse reaction Log’. Adverse events may occur in relation to procedures of Part A and Part B: telemetric pill ingestion; blood sampling/draws; light stimulation; and/or bilateral ocular application of pupil dilator medication. Serious adverse events (SAE’s) reporting will follow HRA procedure for REC notification and subsequent action, and will include any Serious Adverse Events (SARs) or Suspected SUSARs, as defined below.

3.13.1 Definitions

An adverse event (AE) is an untoward medical occurrence in a study participant.

An adverse reaction (AR) is any untoward and unintended response which is related to the outcome data collection for that participant. A serious adverse reaction (SAR) is any AR that:

  • results in death of the clinical trial participant; is life threatening*;

  • requires in-patient hospitalisation or prolongation of existing hospitalisation^;

  • results in persistent or significant disability or incapacity;

  • consists of a congenital anomaly or birth defect;

  • results in any other significant medical event not meeting the criteria above.

A suspected unexpected serious adverse reaction (SUSAR) is any AR that is classified as serious and is suspected to be caused by the outcome data collection.

*Life-threatening in the definition of an SAE or SAR refers to an event where the participant was at risk of death at the time of the event. It does not refer to an event which hypothetically might have caused death if it were more severe.

^Any hospitalisation that was planned prior to randomisation will not meet seriousness criteria. Any hospitalisation that is planned post randomisation will meet the seriousness criteria unless it does not constitute an untoward medical occurrence (e.g. cosmetic elective surgery, social and/or convenience admission, etc.).

3.14 Good clinical practice

3.14.1 Ethical conduct

The study will be conducted in accordance with the principles of the International Conference on Harmonisation Tripartite Guideline for Good Clinical Practice (ICH GCP). Before the study can commence, all necessary approvals will be obtained and any conditions of approvals will be met.

3.14.2 Informed consent

The Investigator is responsible for ensuring informed consent is obtained before any study specific procedures are carried out. The decision of a participant to participate in clinical research is voluntary and should be based on a clear understanding of what is involved. Participants must receive adequate oral and written information – appropriate Participant Information and Informed Consent Forms will be provided. The oral explanation to the participant will be performed by the Investigator or qualified delegated person, and must cover all the elements specified in the Participant Information Sheet and Consent Form. The participant must be given every opportunity to clarify any points they do not understand and, if necessary, ask for more information. The participant must be given sufficient time to consider the information provided. It will be emphasised that the participant may withdraw their consent to participate at any time without loss of benefits to which they otherwise would be entitled. The participant will be informed and agree to their medical records being inspected by regulatory authorities and representatives of the Sponsor(s). The Investigator or delegated member of the study team and the participant will sign and date the Informed Consent Form(s) to confirm that consent has been obtained. The original will be signed in the Investigator Site File (ISF). The participant will receive a copy of the signed consent form and a copy will be filed in the participant’s medical notes and sent to their GP.

3.14.3 Confidentiality

All laboratory specimens, evaluation forms, reports, and other records must be identified in a manner designed to maintain participant confidentiality. All records must be kept in a secure storage area with limited access. Clinical information will not be released without the written permission of the participant. The Investigator and study site staff involved with this study may not disclose or use for any purpose other than performance of the study, any data, record, or other unpublished information, which is confidential or identifiable, and has been disclosed to those individuals for the purpose of the study. Prior written agreement from the Sponsor or its designee must be obtained for the disclosure of any said confidential information to other parties.

3.14.4 Data protection

All Investigators and study site staff involved with this study must comply with the requirements of the appropriate data protection legislation (including the General Data Protection Regulation and Data Protection Act) with regard to the collection, storage, processing and disclosure of personal information. Computers used to collate the data will have limited access measures via user names and passwords. Published results will not contain any personal data that could allow identification of individual participants.

3.14.5 Study record retention

Personal data will be stored for 15 years after study completion on the University of Edinburgh DataVault. For one year following study completion, data will be held in pseudonymised format. After deletion of identifiable data (one year after study completion), the study dataset will effectively become anonymised. Anonymised digital data will be kept for a period of 14 years after the deletion of identifiable data. When the minimum retention period has elapsed, study documentation will be destroyed with permission from the Sponsor.

3.14.6 End of study

The end of study is defined as the last participant’s last visit. The Investigators and/or the Sponsor(s) have the right at any time to terminate the study for clinical or administrative reasons. The end of the study will be reported to the REC, and R&D Office(s) and Sponsor(s) within 90 days, or 15 days if the study is terminated prematurely. The Investigators will inform participants of the premature study closure and ensure that the appropriate follow up is arranged for all participants involved. End of study notification will be reported to the Sponsor(s) via email to researchgovernance@ed.ac.uk. A summary report of the study will be provided to the REC within 1 year of the end of the study.

3.15 Ethical approvals

The HELIOS-BD study received a favourable ethical opinion from the South East Scotland Research Ethics Committee on 20/10/2023 (23/SS/0104). NHS Lothian R&D approvals were granted on 09/11/2023. The HELIOS-BD study is co-sponsored by the University of Edinburgh and NHS Lothian.

3.16 Ethical considerations of the research

1. Ensuring inclusive and representative recruitment:

Our recruitment methods are based on voluntary contact from interested individuals who have been informed of the study either through established research and mental health organisations, or via social media. However, it is known that particular identities are under-represented in medical research, with serious consequences for equitable healthcare. In particular, people from minoritised ethnic groups, people at socioeconomic disadvantage and people with minoritised sexualities and gender identities are under-represented and under-served by research. The reasons for this are many and varied. In this study, we aim to achieve a representative and diverse study population, with equal representation of men and women. We will advertise the study widely, and we will recruit thoughtfully to ensure our sample is representative of the bipolar disorder population in Scotland. We will also provide reimbursement for caring costs (e.g. childcare) to remove barriers to participation for those with caring responsibilities.

2. Preventing undue incentivisation due to participation payments:

Study participants will be reimbursed for their time and travel expenses. However, it is important that financial benefits do not inappropriately incentivise individuals to participate in the research when it is not in their best interests. The participation payment will therefore be advertised in a neutral tone in any study advert materials and in the Participant Information Form. We recognise that offering payment for study participation may increase the possibility of dishonesty from people who want to participate in the research, in order to increase their chances of enrolment. We will address this by using NHS-linked recruitment methods and by corroborating information with medical notes where necessary.

3. Risks and adverse events associated with study procedures:

Some of the study procedures carry risks for adverse events; for example, participants may experience short-term discomfort during the study procedures required for this study. Associated risks will be minimised by ensuring that experienced staff are appropriately trained to conduct the procedures, and that participants are fully informed of all procedures. Participants will be instructed to inform the research team of any health issues or concerns which arise during the study, to make sure they are appropriately cared for. A wellbeing follow-up call is scheduled for all participants 3 days following their final overnight stay to make sure there are no negative impacts of the light delivery protocol.

Further to this, there is a small risk that incidental findings may be identified on the retinal images which may require further investigation. We anticipate the rate of significant or urgent findings to be <1%. Each participant will be told of this risk, as well as it being stated on the participant information sheet. Should we observe unusual signs in the images that might signs of eye problems, anonymised images will be reviewed by the ophthalmologist on our team for checking of incidental findings. If we were to observe any such findings then an appropriate member of the study team would discuss this with the participant and inform their GP so that appropriate further tests and treatments could be arranged as necessary.

4. Making sure the research is relevant and acceptable to people with bipolar disorder:

It is important that the research we conduct is relevant and acceptable to people with bipolar disorder. We are in ongoing consultation with the HELIOS-BD Lived Experience Advisory Panel (LEAP) and volunteers from Bipolar Scotland to make sure this is the case. The study design has already benefited from input from people with lived experience of bipolar disorder.

4 Study Status

Study is active and recruiting participants.

5 Conclusion

HELIOS-BD tests an important and still unresolved hypothesis on bipolar disorder light hypersensitivity and the mechanism of action of lithium at both cellular and systems levels. With this ambitious project, we seek to investigate visual and non-visual responses to light, and associated structural and functional retinal changes, in a bipolar disorder population compared to control participants. Further, the study will test whether lithium acts to correct any altered responses. The results from this project have considerable translational potential and will help us to further understand circadian dysregulation in bipolar disorder, as well as potentially provide insight into therapeutic pathways to prevent acute mood episodes.

Acknowledgements

We would like to thank all of the people with lived experience of bipolar disorder who have contributed to the HELIOS-BD project and helped to shape this research. This includes the focus group participants, those who were interviewed individually, members of Bipolar Scotland and our HELIOS-BD Lived Experience Advisory Panel (LEAP).

Funding Statement

This work was supported by Wellcome [226787].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

[version 2; peer review: 4 approved, 1 approved with reservations]

Data availability

No data are associated with this article.

References

  1. Appaji A, Nagendra B, Chako DM, et al. : Retinal vascular abnormalities in schizophrenia and bipolar disorder: a window to the brain. Bipolar Disord. 2019;21(7):634–641. 10.1111/bdi.12779 [DOI] [PubMed] [Google Scholar]
  2. Bauer M, Glenn T, Achtyes ED, et al. : Variations in seasonal solar insolation are associated with a history of suicide attempts in bipolar I disorder. Int J Bipolar Disord. 2021;9(1): 26. 10.1186/s40345-021-00231-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bullock B, McGlashan EM, Burns AC, et al. : Traits related to bipolar disorder are associated with an increased post-illumination pupil response. Psychiatry Res. 2019;278:35–41. 10.1016/j.psychres.2019.05.025 [DOI] [PubMed] [Google Scholar]
  4. Buysse DJ, Reynolds 3rd CF, Monk TH, et al. : The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. 10.1016/0165-1781(89)90047-4 [DOI] [PubMed] [Google Scholar]
  5. Chellappa SL: Individual differences in light sensitivity affect sleep and circadian rhythms. Sleep. 2020;44(2): zsaa214. 10.1093/sleep/zsaa214 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Duncan WC, Jr, Johnson KA, Wehr TA: Decreased sensitivity to light of the photic entrainment pathway during chronic clorgyline and lithium treatments. J Biol Rhythms. 1998;13(4):330–346. 10.1177/074873098129000165 [DOI] [PubMed] [Google Scholar]
  7. Fernandes TMP, Andrade SM, de Andrade MJO, et al. : Colour discrimination thresholds in type 1 Bipolar Disorder: a pilot study. Sci Rep. 2017;7(1): 16405. 10.1038/s41598-017-16752-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fernandes TP, Felisberti FM, Shoshina II, et al. : Combined influence of medication and symptom severity on visual processing in bipolar disorder. J Psychiatr Res. 2022;147:135–141. 10.1016/j.jpsychires.2022.01.010 [DOI] [PubMed] [Google Scholar]
  9. Fernandes TP, Silverstein SM, Almeida NL, et al. : Visual impairments in type 1 bipolar disorder. World J Biol Psychiatry. 2019;20(10):790–798. 10.1080/15622975.2019.1628302 [DOI] [PubMed] [Google Scholar]
  10. Ferrier IN, Ferrie LJ, Macritchie KA: Old drug, new data: revisiting… Lithium therapy. Adv Psychiatr Treat. 2006;12(4):256–264. 10.1192/apt.12.4.256 [DOI] [Google Scholar]
  11. Garcia-Martin E, Gavin A, Garcia-Campayo J, et al. : Visual function and retinal changes in patients with bipolar disorder. Retina. 2019;39(10):2012–2021. 10.1097/IAE.0000000000002252 [DOI] [PubMed] [Google Scholar]
  12. Geoffroy PA, Bellivier F, Scott J, et al. : Seasonality and bipolar disorder: a systematic review, from admission rates to seasonality of symptoms. J Affect Disord. 2014;168:210–223. 10.1016/j.jad.2014.07.002 [DOI] [PubMed] [Google Scholar]
  13. Grof P, Duffy A, Cavazzoni P, et al. : Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63(10):942–947. 10.4088/jcp.v63n1013 [DOI] [PubMed] [Google Scholar]
  14. Hallam KT, Begg DP, Olver JS, et al. : Abnormal dose-response melatonin suppression by light in bipolar type I patients compared with healthy adult subjects. Acta Neuropsychiatr. 2009;21(5):246–255. 10.1111/j.1601-5215.2009.00416.x [DOI] [PubMed] [Google Scholar]
  15. Hallam KT, Olver JS, Horgan JE, et al. : Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers. Int J Neuropsychopharmacol. 2005;8(2):255–9. 10.1017/S1461145704004894 [DOI] [PubMed] [Google Scholar]
  16. Harris PA, Taylor R, Minor BL, et al. : The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208. 10.1016/j.jbi.2019.103208 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Harris PA, Taylor R, Thielke R, et al. : Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. 10.1016/j.jbi.2008.08.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Henriksen TE, Skrede S, Fasmer OB, et al. : Blue-blocking glasses as additive treatment for mania: a randomized placebo-controlled trial. Bipolar Disord. 2016;18(3):221–232. 10.1111/bdi.12390 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hester L, Dang D, Barker CJ, et al. : Evening wear of blue-blocking glasses for sleep and mood disorders: a systematic review. Chronobiol Int. 2021;38(10):1375–1383. 10.1080/07420528.2021.1930029 [DOI] [PubMed] [Google Scholar]
  20. Klein PS, Melton DA: A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93(16):8455–8459. 10.1073/pnas.93.16.8455 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lam RW, Berkowitz AL, Berga SL, et al. : Melatonin suppression in bipolar and unipolar mood disorders. Psychiatry Res. 1990;33(2):129–134. 10.1016/0165-1781(90)90066-e [DOI] [PubMed] [Google Scholar]
  22. Lewy AJ, Nurnberger JI, Wehr TA, et al. : Supersensitivity to light: possible trait marker for manic-depressive illness. Am J Psychiatry. 1985;142(6):725–727. 10.1176/ajp.142.6.725 [DOI] [PubMed] [Google Scholar]
  23. Lewy AJ, Wehr TA, Goodwin FK, et al. : Manic-depressive patients may be supersensitive to light. Lancet. 1981;1(8216):383–384. 10.1016/s0140-6736(81)91697-4 [DOI] [PubMed] [Google Scholar]
  24. Liboiron M, Zahara A, Schoot I: Community peer review: a method to bring consent and self-determination into the sciences.(2018060104). Preprints. 2018; 2018060104. 10.20944/preprints201806.0104.v1 [DOI] [Google Scholar]
  25. Madsen HØ, Ba-Ali S, Heegaard S, et al. : Melanopsin-mediated pupillary responses in bipolar disorder—A cross-sectional pupillometric investigation. Int J Bipolar Disord. 2021;9(1): 7. 10.1186/s40345-020-00211-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. McCarthy MJ, Gottlieb JF, Gonzalez R, et al. : Neurobiological and behavioral mechanisms of circadian rhythm disruption in bipolar disorder: a critical multi-disciplinary literature review and agenda for future research from the ISBD task force on chronobiology. Bipolar Disord. 2022;24(3):232–263. 10.1111/bdi.13165 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Measuring health and disability: Manual for WHO disability assessment schedule (‎WHODAS 2.0)‎.2010. Reference Source
  28. Merikangas KR, Jin R, He JP, et al. : Prevalence and correlates of Bipolar Spectrum Disorder in the World Mental Health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–251. 10.1001/archgenpsychiatry.2011.12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Mertens J, Wang QW, Kim Y, et al. : Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature. 2015;527(7576):95–99. 10.1038/nature15526 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Moon JH, Cho CH, Son GH, et al. : Advanced circadian phase in mania and delayed circadian phase in mixed mania and depression returned to normal after treatment of bipolar disorder. EBioMedicine. 2016;11:285–295. 10.1016/j.ebiom.2016.08.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Nathan PJ, Burrows GD, Norman TR: Melatonin sensitivity to dim white light in affective disorders. Neuropsychopharmacology. 1999;21(3):408–413. 10.1016/S0893-133X(99)00018-4 [DOI] [PubMed] [Google Scholar]
  32. Nurnberger JI, Adkins S, Lahiri DK, et al. : Melatonin suppression by light in euthymic bipolar and unipolar patients. Arch Gen Psychiatry. 2000;57(6):572–579. [DOI] [PubMed] [Google Scholar]
  33. Prasannakumar A, Kumar V, Mailankody P, et al. : A systematic review and meta-analysis of optical coherence tomography studies in schizophrenia, bipolar disorder and major depressive disorder. World J Biol Psychiatry. 2023;24(8):707–720. 10.1080/15622975.2023.2203231 [DOI] [PubMed] [Google Scholar]
  34. Ritter P, Soltmann B, Sauer C, et al. : Supersensitivity of patients with bipolar i disorder to light-induced phase delay by narrow bandwidth blue light. Biol Psychiatry Glob Open Sci. 2021;2(1):28–35. 10.1016/j.bpsgos.2021.06.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Ritter P, Wieland F, Skene DJ, et al. : Melatonin suppression by melanopsin-weighted light in patients with bipolar I disorder compared to healthy controls. J Psychiatry Neurosci. 2020;45(2):79–87. 10.1503/jpn.190005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Roenneberg T, Wirz-Justice A, Merrow M: Life between clocks: daily temporal patterns of human chronotypes. J Biol Rhythms. 2003;18(1):80–90. 10.1177/0748730402239679 [DOI] [PubMed] [Google Scholar]
  37. Scott J, Etain B, Manchia M, et al. : An examination of the quality and performance of the Alda scale for classifying lithium response phenotypes. Bipolar Disord. 2020;22(3):255–265. 10.1111/bdi.12829 [DOI] [PubMed] [Google Scholar]
  38. Seggie J, Steiner M, Wright N, et al. : The effect of lithium on pupillary response to pulses of light in sheep. Psychiatry Res. 1989;30(3):305–311. 10.1016/0165-1781(89)90021-8 [DOI] [PubMed] [Google Scholar]
  39. Smith FE, Thelwall PE, Necus J, et al. : 3D 7Li magnetic resonance imaging of brain lithium distribution in bipolar disorder. Mol Psychiatry. 2018;23(11):2184–2191. 10.1038/s41380-018-0016-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Swope CB, Rong S, Campanella C, et al. : Factors associated with variability in the melatonin suppression response to light: a narrative review. Chronobiol Int. 2023;40(4):542–556. 10.1080/07420528.2023.2188091 [DOI] [PubMed] [Google Scholar]
  41. Uprety S, Adhikari P, Feigl B, et al. : Melanopsin photoreception differentially modulates rod-mediated and cone-mediated human temporal vision. iScience. 2022;25(7): 104529. 10.1016/j.isci.2022.104529 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Ustün TB, Chatterji S, Kostanjsek N, et al. : Developing the world health organization disability assessment schedule 2.0. Bull World Health Organ. 2010;88(11):815–823. 10.2471/BLT.09.067231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Watson LA, Phillips AJK, Hosken IT, et al. : Increased sensitivity of the circadian system to light in delayed sleep-wake phase disorder. J Physiol. 2018;596(24):6249–6261. 10.1113/JP275917 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Whalley LJ, Perini T, Shering A, et al. : Melatonin response to bright light in recovered, drug-free, bipolar patients. Psychiatry Res. 1991;38(1):13–19. 10.1016/0165-1781(91)90048-t [DOI] [PubMed] [Google Scholar]
Wellcome Open Res. 2024 Nov 12. doi: 10.21956/wellcomeopenres.25555.r107242

Reviewer response for version 2

Angus C Burns 1,2,2,3

The authors have put together a novel and exciting protocol that aims to examine the role of light exposure and light sensitivity in the aetiology of bipolar disorder. This project is well motivated by prior literature on a putative role for non-visual light sensitivity in bipolar disorder and seeks to identify plausible mechanisms at the level of the retina. The project involves three study arms designed to examine whether bipolar disorder patients exhibit (A) an enhanced non-visual response of the circadian clock to light as measured by melatonin suppression, (B) aberrant visual, cortical and pupillary responses to light of different wavelengths designed to target different photoreceptor systems and (C) distinct microstructural changes in the retina, as compared to healthy controls with no history of a psychiatric disorder. As an additional layer of investigation and analysis, the authors will examine whether lithium treatment will act as a moderator of hypothesised differences between bipolar disorder cases and controls, such that those treated with lithium are closer to controls in phenotypic presentation. I note that this protocol has undergone a revision in response to reviews from several colleagues with updates to inclusion/exclusion criteria and pupillometry methods. The proposed methodology is overall well designed to address the proposed aims and I applaud the involvement of individuals with lived experience of bipolar disorder. However, I have some further questions and comments in particular relating to the melatonin suppression protocol. 

3.4 Study Design

You state that “this is an experimental study”, which I don’t think is correct for your main aims and hypotheses which relate to differences in melatonin suppression, pupillary responses and retinal microstructure between diagnosis groups. As the case-control status of bipolar versus healthy control participants is not manipulated or randomised this study is perhaps better described as an observational case-control study with experimental manipulation within groups (e.g. light exposure manipulation) or a quasi-experimental study. This also applies to the lithium moderation hypothesis which as far as I can tell is not going to be randomized and/or manipulated. I am noting that there is a reference to randomisation in 3.13.1 Definitions, is this related to the actual study procedures?

3.4.4.1 Baseline study visit

Just noting to include the MEQ here and in 3.7.1.2 Baseline study visit as a measure of chronotype which is referred to in 3.10.2.1 Part A. I think it is good to have both since they tap into different dimensions of chronotype.

Part A: Overnight experimental assessments

  1. It is great that the authors have included a baseline/dark control for this study, and I find the use of a core-body temperature measurement interesting. The aim of this is to time the administration of the light exposure on Study Day 2 relative to the CBT nadir, i.e., standardizing the circadian phase of administration. This is a great idea in principle however I am concerned by the fact that participants are free to sleep from 10pm to 6am. Sleep causes a dramatic masking of the core body temperature rhythm (see Figures 3 and 5 in this paper 1). As such, it is gold-standard practice to measure CBT under constant routine procedures with participants maintaining wakefulness in order to accurately measure intrinsic timing. Under the current protocol, you are likely to observe different CBT profiles to the true rhythm. Can the authors provide a rationale for the current methodology? Is it possible to switch this to a constant routine to ensure accurate CBT rhythm measurement?

  2. Following from this, the masking effect of sleep differs by the circadian phase of sleep onset. I note that the sleep onset times are fixed for both groups and not based on habitual sleep onset and offset. This means that the circadian phase of sleep onset will likely systematically differ between-groups given a proposed circadian delay amongst bipolar patients. This may result in a systematic bias in the estimate of CBT minima between groups and result in the timing of the light exposure at different circadian phases between groups. I think the authors will want to avoid this as it could result in the occlusion of true group differences.

  3. Relating to the above points, I note that you propose to use the mid-point of sleep based on sleep diaries for the 10 days prior to time the light exposure if the CBT monitoring fails to detect a minimum. This is a good idea in general and I think could be a more accurate alternative procedure to the CBT measurement approach if you are not interested in running a constant routine. In that case, I would suggest imposing a self-selected fixed sleep-wake schedule for the 10 days prior to lab visit (to ensure stable entrainment) and then time the light exposure based on the midpoint of sleep. This should be checked with objective actigraphy. Currently, I believe the participants are on a free schedule prior to the lab visits. This may not be ideal due to the large variability of sleep-wake timing behaviour in free-living humans (which is potentially pronounced in bipolar disorder) and may limit the utility of a sleep-diary based midpoint for timing the light exposure. Alternatively, one could run a constant routine to ensure accurate measurement of the CBT rhythm to time the light exposure.

  4. I am wondering if based on the power analysis you have selected a light level for the exposure? Further, I was wondering why a 30-minute exposure only was selected, as there are temporal dynamics to melatonin suppression that could be interesting as well.

Is the study design appropriate for the research question?

Partly

Is the rationale for, and objectives of, the study clearly described?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Reviewer Expertise:

Circadian rhythms, sleep, light exposure, melatonin suppression, genetics, psychiatric health.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

References

  • 1. : Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. J Neurosci .1995;15(5 Pt 1) : 10.1523/JNEUROSCI.15-05-03526.1995 3526-38 10.1523/JNEUROSCI.15-05-03526.1995 [DOI] [PMC free article] [PubMed] [Google Scholar]
Wellcome Open Res. 2024 Nov 11. doi: 10.21956/wellcomeopenres.25555.r107248

Reviewer response for version 2

Joey W Y Chan 1

This is a timely and important research study to investigate the largely unknown impact of light sensitivity, retinal functions, and lithium in patients with bipolar disorder. The study seeks to unveil the potential neurobiological mechanism of light contributing to circadian disruptions in bipolar disorder and the therapeutic mechanism of lithium. This is a relatively large study incorporated both state-of-the-art visual/ retinal assessments and in-depth circadian measurements. The rationale and objectives of the study are well-defined. There are established patient networks for the recruitment and early involvement of patients to delineate an acceptable research protocol.

I have some minor queries and comments based on the version2:

Background 2.2: “A hypo- or hyper-sensitive response to light within the photoreceptive pathway can therefore result in a shifted circadian phase and dysregulation of biological rhythms.”

In healthy young adults, a more pronounced PIPR was associated with a more delayed sleep (van der Meijden et al., 2016). On the other hand, we found that a larger PIPR correlated with an earlier acrophase of the actigraphic rest-activity rhythm (Chan et al., 2024). While the light

sensitivity may influence the melatonin levels, the shift of the circadian phase would also be dependent on the light exposure pattern. It is very thoughtful to measure continuous light exposure in the study. How would the light exposure data be analysed?

3.4.4.3 Part B: Retinal assessments: Session 1: Pupillometry

It would be helpful if the authors can provide greater details about the light stimulus, pupillometric protocol and definition of PIPR in the methods. Given the circadian modulation of PIPR (Munch et al., 2012; Zele et al., 2011), would PIPR be conducted according to the individual circadian time in this study? Or constrained to a certain time of the day, as in other studies (Bullock et al., 2019)?

3.6.2 Inclusion criteria: BD non-lithium participant group:

The difference between the BD-lithium and BD non-lithium group is the absence of lithium treatment over the past six months prior to entry of the study. Other psychotropics, e.g. sodium valproate (Hallam et al., 2005), SSRI (McGlashan et al., 2018), have also be shown to influence light sensitivity, would the effects of these medications on light sensitivity be accounted for in the analysis?

3.6.3 Exclusion criteria: All participants: blindness, visual impairment, existing eye disease such as glaucoma or age-related macular degeneration, retinal surgery etc Presence of cataract may reduce the amount of light reaching the retina in the pupillary response measurements. Given that comprehensive eye assessment is available, it would be helpful to measure lens opacity if cataract is not an exclusion.

Is the study design appropriate for the research question?

Yes

Is the rationale for, and objectives of, the study clearly described?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Reviewer Expertise:

Bright light therapy, circadian rhythms, pupillary response, affective disorders

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

References

  • 1. : Traits related to bipolar disorder are associated with an increased post-illumination pupil response. Psychiatry Res .2019;278: 10.1016/j.psychres.2019.05.025 35-41 10.1016/j.psychres.2019.05.025 [DOI] [PubMed] [Google Scholar]
  • 2. : Attenuated melanopsin-mediated post-illumination pupillary response (PIPR) is associated with reduced actigraphic amplitude and mesor in older adults. Sleep .2024; 10.1093/sleep/zsae239 10.1093/sleep/zsae239 [DOI] [PubMed] [Google Scholar]
  • 3. : Effect of sodium valproate on nocturnal melatonin sensitivity to light in healthy volunteers. Neuropsychopharmacology .2005;30(7) : 10.1038/sj.npp.1300739 1400-4 10.1038/sj.npp.1300739 [DOI] [PubMed] [Google Scholar]
  • 4. : The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose. Psychopharmacology (Berl) .2018;235(11) : 10.1007/s00213-018-5019-0 3201-3209 10.1007/s00213-018-5019-0 [DOI] [PubMed] [Google Scholar]
  • 5. : Circadian and wake-dependent effects on the pupil light reflex in response to narrow-bandwidth light pulses. Invest Ophthalmol Vis Sci .2012;53(8) : 10.1167/iovs.12-9494 4546-55 10.1167/iovs.12-9494 [DOI] [PubMed] [Google Scholar]
  • 6. : Individual Differences in Sleep Timing Relate to Melanopsin-Based Phototransduction in Healthy Adolescents and Young Adults. Sleep .2016;39(6) : 10.5665/sleep.5858 1305-10 10.5665/sleep.5858 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. : The circadian response of intrinsically photosensitive retinal ganglion cells. PLoS One .2011;6(3) : 10.1371/journal.pone.0017860 e17860 10.1371/journal.pone.0017860 [DOI] [PMC free article] [PubMed] [Google Scholar]
Wellcome Open Res. 2024 Oct 28. doi: 10.21956/wellcomeopenres.25555.r107247

Reviewer response for version 2

Oleg Kovtun 1

The protocol by Roguski et al. is a part of broader effort funded by the Wellcome Trust to investigate whether light hypersensitivity causes circadian rhythm disruption in bipolar disorder. The three-pronged longitudinal study protocol outlines a rigorous plan to evaluate the contribution of retinal pathophysiology to hypothesized light hypersensitivity in BD patients by examining (i) light-induced melatonin suppression, (ii) retinal function, and (iii) retinal microstructure, compared to healthy controls. In addition, the protocol seeks to determine whether the mood stabilizer lithium reduces heightened light sensitivity and mitigates retinal pathophysiological changes. 

The rationale for the protocol is supported by a broad consensus that circadian disturbances are a hallmark feature across various BD phenotypes. Light (and its seasonal patterns) serves as a critical cue for entraining circadian rhythms and has emerged as a powerful therapeutic tool (e.g., bright-light therapy (BLT) and blue-light blocking sunglasses) to restore natural circadian rhythms, thereby reducing symptoms and functional impairment in BD. Several studies suggested that hypersensitivity to light may be a trait marker for BD, which is in excellent agreement with the hypothesis put forth by Roguski et al. Furthermore, investigating the link between retinal physiology and light sensitivity in BD addresses several central questions in the future research agenda from the International Society for Bipolar Disorders (ISBD) Chronobiology Task Force (CTF) [https://doi.org/10.1111/bdi.13165].

The protocol is meticulously developed and organized:

  • The mechanistic basis for investigation is clearly defined in the introduction;

  • Lived experience is incorporated into the protocol and remains central throughout the study, from the participant screening stage to data interpretation to results dissemination;

  • Inclusion/exclusion criteria are appropriate and clearly defined;

  • A structured clinical assessment is in place to confirm a diagnosis of BD and clinical euthymia prior to enrollment. The assessment includes complementary questionnaires to ensure rigor;

  • The on-site experimental assessments are described in appropriate detail and were designed to minimize the burden and risk of adverse events;

  • Adequate data management protocols are in place to protect participant’s sensitive personal data;

  • Ethical approvals were granted in accordance with the principles of good clinical practice.

The authors fully addressed all concerns raised by the reviewers in the first round. However, I do have several minor comments:

  1. In section 2.3, Roguski et al. describe the observed seasonal patterns in mood episode-related hospital admissions and suicide attempts in BD. Recognizing the importance of seasonality, the authors included a Modified Seasonal Pattern Assessment Questionnaire (m-SPAQ) in the baseline assessment. Beyond that, it is not clear how seasonality is incorporated into Part A overnight experimental assessments and subsequent data analysis. Yes, there is a plan to conduct Part A between the months of September-April inclusive to avoid the effects of too much light at night during the summer months. However, is there a plan to assign study participants into Fall, Winter, Spring subgroups to capture seasonality effects?

  2. The association of BD with medical comorbidities is well-documented. Recent evidence also suggests higher incidence rates of retinal diseases in BD patients compared to healthy controls [https://doi.org/10.1111/pcn.13326]. Additionally, lithium is associated with ophthalmic adverse effects, including exophthalmos, abnormal eye movements, photophobia, and abnormal tear film [https://doi.org/10.1097/YIC.0000000000000295]. Roguski et al. anticipate that incidental findings may be identified on the retinal images, with the anticipated rate of <1% - is there a reference to support this number? Appropriately, the medical exclusion criteria include visual impairments, existing eye disease (glaucoma or age-related macular degeneration), and previous surgery on the retina. However, have the authors considered assessing medical comorbidities that are risk factors for retinal health (e.g., type 2 diabetes, CVD, hypertension) as potential confounding variables?

  3. Section 3.10.2.1. Part A lists MEQ (Morningness-Eveningness Questionnaire?) total score for chronotype as a secondary outcome measure, but I couldn’t find it anywhere else in the protocol.

  4. Section 3.16.3 (last paragraph): “ Should we observe unusual signs in the images that might signs of eye problems,…” – might indicate signs?

Overall, this is a comprehensive and rigorously structured protocol for an important and much-needed study in BD etiology. I look forward to seeing the results.

Is the study design appropriate for the research question?

Yes

Is the rationale for, and objectives of, the study clearly described?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Reviewer Expertise:

Seasonality in mood disorders, circadian rhythm, accelerometry, digital mental health

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Wellcome Open Res. 2024 May 6. doi: 10.21956/wellcomeopenres.22755.r76485

Reviewer response for version 1

Karen Hallam 1

The rationale for this research is strong and circadian rhythms have long been an identified marker of the illness and disturbances of these a key treatment focus for clinicians. The authors have identified several key papers that span over 50 years now, with many of these identifying similar trends in melatonin suppression.

IN relation to the effects of lithium carbonate and other lithium preparations on light sensitivity, there is a strong rationale for investigating this response. It is worth noting that the authors have not included some of our previous research in healthy volunteers showing a direct effect of lithium carbonate on reducing melatonin sensitivity to light in health volunteers, a finding that implies one potential physiological impact of lithium that may be involved in its management of bipolar disorders (see Hallam et al, 2005(Ref 2)). This further highlights the need to better understand and potential associate lithium levels with light sensitivity in large scale studies such as that being proposed. It is notable that we identified similar (albeit weaker) changes in melatonin sensitivity to light with sodium valproate treatment (Hallam et al., 2005 (Ref 3)).

The recruitment approach is excellent and the capacity to use databases like SHARE provide a new method to manage selection biases in research recruitment. This will likely deliver data on more participants across functional levels, something that may further the research from previously hospital recruited participant groups. In terms of the study aims and methodology, the aims are clearly defined and there is a sound rationale. The study is large and has a well-developed methodology. I would suggest considerations for the authors for their methodology to improve the outcomes or to consider in more depth below.

In terms of measurement tools, confirmation of their diagnosis outside of clinical interview seems to have been excluded. It would be suggested that a formal screening questionnaire (e.g. the SCID) is utilised to standardise the assessment process. This may be particularly useful for differentiating bipolar type I and II populations. Notably, when assessing lifestyle factors, the team may want to investigate caffeine use (not covered in the AUDIT), which falls outside the AUDIT but has a clear impact on sleep quality for many people and potentially populations with BPAD (see Frigerio S,et.al., 2021(Ref 1)). It would also be logical to screen for other substance use.

In relation to screening, it would typically be expected that the investigators would assess manic and/or hypomanic symptoms at the time of testing and study inclusion. Typically, we would encourage the use of the Young Mania Rating Scale (YMRS) or similar to 1. Ensure someone can consent to the research and 2. To identify their level of active manic/hypomanic symptoms. This should be re-administered for any further testing sessions.

The procedure seems appropriate and scientifically rigorous, utilising highly sensitive measurement approaches that would not have been previously available to researchers (e.g. temperature pill). Adding the details of the brightness of the full spectrum white light (e.g. using a luxometer) would be a helpful addition to assess against past studies.

Finally, in terms of methodology, I am unsure of why the detailed ocular investigations follow the overnight melatonin measurement. It would make more sense for these tests to be conducted first to ensure the individual is appropriate for the study as any deficits in these measures may impact the participants results.

This is a fascinating and rigorously developed study with a large population that may finally answer the question around melatonin light sensitivity and its role in bipolar disorders. The research is important, both for the basic science it is uncovering as well as its clinical implications for interventions. I wish the research team the very best for this important project.

Is the study design appropriate for the research question?

Yes

Is the rationale for, and objectives of, the study clearly described?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Reviewer Expertise:

Endophenotype research and application of biological theories to clinical interventions, particularly in the area of mood disorders and chronic stress.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

References

  • 1. : The impact of caffeine consumption on clinical symptoms in patients with bipolar disorder: A systematic review. Bipolar Disord .2021;23(3) : 10.1111/bdi.12990 241-251 10.1111/bdi.12990 [DOI] [PubMed] [Google Scholar]
  • 2. : Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers. Int J Neuropsychopharmacol .2005;8(2) : 10.1017/S1461145704004894 255-9 10.1017/S1461145704004894 [DOI] [PubMed] [Google Scholar]
  • 3. : Effect of sodium valproate on nocturnal melatonin sensitivity to light in healthy volunteers. Neuropsychopharmacology .2005;30(7) : 10.1038/sj.npp.1300739 1400-4 10.1038/sj.npp.1300739 [DOI] [PubMed] [Google Scholar]
Wellcome Open Res. 2024 Oct 1.
Amber Roguski 1

We thank the reviewer for their thoughtful and comprehensive review of the HELIOS-BD protocol, and for their fundamental contributions to the field. Our responses are as follows, and we respond specifically to the below points for clarification or to indicate an update to the manuscript.

1. It is worth noting that the authors have not included some of our previous research in healthy volunteers showing a direct effect of lithium carbonate on reducing melatonin sensitivity to light in health volunteers, a finding that implies one potential physiological impact of lithium that may be involved in its management of bipolar disorders (see Hallam et al, 2005(Ref 2)). The protocol introduction has been updated to include this study, which provides important evidence for a role for lithium is regulation of circadian and melatonergic signalling. Thank you for highlighting this oversight.

2. In terms of measurement tools, confirmation of their diagnosis outside of clinical interview seems to have been excluded. It would be suggested that a formal screening questionnaire (e.g. the SCID) is utilised to standardise the assessment process.  All potential participants with bipolar have their bipolar diagnosis confirmed by a psychiatrist during the screening appointment using the SCID. The responses to all SCID questions are stored for later analysis, for example, to stratify participants according to bipolar Type and polarity of symptoms (as suggested by the reviewer).

3. Notably, when assessing lifestyle factors, the team may want to investigate caffeine use (not covered in the AUDIT), which falls outside the AUDIT but has a clear impact on sleep quality for many people and potentially populations with BPAD (see Frigerio S,et.al., 2021(Ref 1)). It would also be logical to screen for other substance use. Caffeine use is not covered during the screening appointment, but we do gain detailed insight into caffeine consumption during the Part A procedure when participants fill out a consensus sleep diary for 12 days. This asks for details relating to consumption of caffeine, alcohol and medications. During the screening appointment, all potential participants are questioned relating to their alcohol and substance use and are not eligible to participate in the study if harmful or dependent use is indicated.

4. In relation to screening, it would typically be expected that the investigators would assess manic and/or hypomanic symptoms at the time of testing and study inclusion. -> Euthymic mood state is determined during the screening procedure, using the Structured Clinical Interview for DSM Disorders (SCID), administered by one of the research team (who has been trained in the SCID use). The majority of study activities occur within a short window following the screening appointment and euthymic mood state is assumed at these appointments. Participants are instructed to inform the study team if they experience a mood episode at any point during their participation. Eligibility criteria, including mood symptoms, are assessed by trained members of the research team prior to all study visits.  

5. I am unsure of why the detailed ocular investigations follow the overnight melatonin measurement. It would make more sense for these tests to be conducted first to ensure the individual is appropriate for the study as any deficits in these measures may impact the participants results. The naming of the Part A, B and C appointments does not reflect their ordering in practice. Typically, participants attend the Baseline appointment and then their first Part C (retinal imaging) appointment in quick succession. We can therefore very quickly identify any previously undiscovered ocular issues in a timeframe very close to the enrolment of the participant. Appropriate action can then be taken (e.g. exclusion of the participant from further study activities). The Part A and Part B appointments are scheduled in the following months according to availability of the participant and the research team. Only Part C 9- and 18-month follow-up appointments must be scheduled within a strict timeframe – the remaining appointments are flexible in their scheduling.

Wellcome Open Res. 2024 Mar 20. doi: 10.21956/wellcomeopenres.22755.r76484

Reviewer response for version 1

Yuichi Esaki 1

Reviewer comment:

Light manipulation, including bright light therapy and dark therapy, is widely used for bipolar disorder in clinical practice. Nevertheless, light sensitivity in bipolar disorder is debatable. Also, lithium is the first-line treatment in bipolar disorder, but the underlying mechanisms remain unclear. Therefore, clarifying these is very important in advancing the mechanisms and treatments for bipolar disorder.

This study protocol investigates an important and still unresolved hypothesis on bipolar disorder light hypersensitivity and the mechanism of action of lithium. This study provides three parts: Part A: Non-visual responses, including sleep/wake cycle, dim light melatonin onset, and core body temperature, Part B: Retinal sensitivity, including visual, cortical, and pupillary, Part C: Retinal imaging. Additionally, this study tests not only comparing patients with bipolar disorder and control participants but also comparing people with bipolar disorder either taking, or not taking, lithium.

This is a very interesting study, and I cannot wait to see the results.

I have some comments.

1. Figure 2.

Do the participants take part in all parts, including Part A, B, and C? Or do they take part in only one part?

2. Page 9. 3.4.4.3 Part B: Retinal assessments

“Experimental assessments will be conducted at the Colour and EEG laboratories (Dugald Stewart Building, University of Edinburgh) between the months of September–April inclusive to avoid the effects of too much light at night during the summer months.”

Page 11. 3.5 Data collection/participation windows

“Baseline, Part B and Part C study visits and data collection will take place throughout the year.”

Which is correct? Will Part B study data collection take place between the months of September–April or throughout the year?

3. Page 11. 3.6 Study population

This is a longitudinal study. What happens if a participant taking lithium stops taking it during follow-up? Drop out? Or will the data be included in the analysis? Also, what happens if a participant not taking lithium starts taking it during follow-up?

4. Page 12. BD Lithium participant group

Who and how determine clinically euthymic of the participants? For example, the International Society for Bipolar Disorders Task Force recommends a MADRS or YMRS score of <8 points to indicate symptomatic remission of bipolar depression or mania, respectively (Tohen et al., 2009). Do the authors assess mood symptoms at the baseline assessment?

5. Table 1.

To facilitate understanding of Table 1 and the manuscript, I suggest that each assessment item be numbered to match the manuscript.

6. Page 15.

Regarding the AX3 actigraphy device (Axivity, UK) and ActLumus light logger (Condor Instruments, Brazil), are these devices validated in the previous studies? If so, please add the references.

Is the study design appropriate for the research question?

Yes

Is the rationale for, and objectives of, the study clearly described?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Reviewer Expertise:

Psychiatry, Chronobiology, in particular light exposure

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Wellcome Open Res. 2024 Apr 18.
Amber Roguski 1

We thank the reviewer for their careful consideration of the HELIOS-BD study and their thoughtful questions and suggestions. Our responses are as follows, and we will make amendments to the manuscript in due course to provide further clarification on the below points.

Reviewer Comment:

1. Figure 2.

Do the participants take part in all parts, including Part A, B, and C? Or do they take part in only one part? -

A) Participants are expected to complete all parts of the study (Baseline, Part A-C) and are recruited onto the study under that expectation.

Reviewer Comment:

2. Page 9. 3.4.4.3 Part B: Retinal assessments

“Experimental assessments will be conducted at the Colour and EEG laboratories (Dugald Stewart Building, University of Edinburgh)  between the months of September–April inclusive to avoid the effects of too much light at night during the summer months.”

Page 11. 3.5 Data collection/participation windows

“Baseline,  Part B and Part C study visits and data collection will take place throughout the year.”

Which is correct? Will Part B study data collection take place between the months of September–April or throughout the year?

A) Thank you for highlighting this inconsistency – Baseline, Part B and Part C appointments will take place throughout the year. Only Part A appointments are stopped during the months of May – August (inclusive). We will amend the manuscript accordingly.

Reviewer Comment:

3. Page 11. 3.6 Study population

This is a longitudinal study. What happens if a participant taking lithium stops taking it during follow-up? Drop out? Or will the data be included in the analysis? Also, what happens if a participant not taking lithium starts taking it during follow-up?

A) Inclusion criteria for the two bipolar groups state that participants must have been taking lithium consistently for the past 6 months (bipolar on lithium group) or have not taken lithium for the past 6 months (bipolar not on lithium group). A change in lithium medication, either stopping or starting, would therefore serve as an exclusion criterion and make the participant in question ineligible for continued participation. If a participant therefore has a lithium-related medication change, they are withdrawn from the study. Their data up to the change would be kept and included in analyses.

Reviewer Comment:

4. Page 12. BD Lithium participant group

Who and how determine clinically euthymic of the participants? For example, the International Society for Bipolar Disorders Task Force recommends a MADRS or YMRS score of <8 points to indicate symptomatic remission of bipolar depression or mania, respectively (Tohen et al., 2009). Do the authors assess mood symptoms at the baseline assessment?

A) Euthymic mood state is determined during the screening procedure, using the Structured Clinical Interview for DSM Disorders (SCID), administered by one of the research team (who has been trained in the SCID use). The majority of study activities occur within a short window following the screening appointment and euthymic mood state is assumed at these appointments. Participants are instructed to inform the study team if they experience a mood episode at any point during their participation. Eligibility criteria, including mood symptoms, are assessed prior to all study visits.

Reviewer Comment:

5. Table 1.

To facilitate understanding of Table 1 and the manuscript, I suggest that each assessment item be numbered to match the manuscript.

A) Thank you for this suggestion – we will amend the manuscript accordingly.

Reviewer Comment:

6. Page 15.

Regarding the AX3 actigraphy device (Axivity, UK) and ActLumus light logger (Condor Instruments, Brazil), are these devices validated in the previous studies? If so, please add the references. 

A)  AX3 device has been validated in several adult populations for sleep and activity measures. ActLumus device has not yet been clinically validated. We will amend the manuscript accordingly to include references regarding the AX3 validation studies.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Availability Statement

    No data are associated with this article.


    Articles from Wellcome Open Research are provided here courtesy of The Wellcome Trust

    RESOURCES